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Background: Epilepsy is a common neurological disease and occurs in 0.7-1.3 % of 
the general population. It is associated with comorbid mental disorders such as 
depression and anxiety, and with a high risk for adverse outcome during pregnancy 
and delivery. Epilepsy affects people of all ages, but especially among young people it 
represents a challenge in how to cope with the disease. This makes young people with 
epilepsy a vulnerable group. 
Aims: We hypothesized that young people with epilepsy have more eating disorders 
than the general population, and wanted to determine the prevalence of eating 
disorders among young people with epilepsy. A particular focus was put on pregnant 
women with epilepsy (WWE). We also wanted to investigate how comorbid eating 
disorders influence outcome of pregnancies in WWE. A second hypothesis we 
investigated was that young people with epilepsy are more overweight, and that such 
overweight leads to an increased risk for an adverse pregnancy-outcome in WWE. 
Material and methods: We used the Norwegian Mother and Child Cohort Study 
(MoBa) to study pregnancies in WWE. More than 100.000 women were included in 
this cohort, whereas 706 women reported a diagnosis of epilepsy. We compared 
pregnancies in women with and without epilepsy in relation to eating disorders and 
overweight, and also pregnancy-outcome. MoBa is linked to the Norwegian Medical 
Birth Registry (MBRN). Secondly we used the Health Profile for Children and Youth 
in Akershus Study to study prevalence of eating disorders among youth with epilepsy 
of both genders. We investigated also additional variables such as overweight, diet 
and physical activity. 
Results: We found that WWE have an increased rate of binge eating disorder 
compared to women without epilepsy. WWE were also more overweight and obese 
than the general population. Both of these variables were associated with adverse 
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outcome during pregnancy and delivery in WWE. Young people with epilepsy in 
Akershus were more likely to have had contact with health personnel due to eating 
disorders than the referent.  
Conclusion: Pregnancies in WWE have a higher risk of adverse outcome. An 
increased rate of overweight and weight inducing eating disorders are contributing 
factors to this. The increased rate of eating disorders among people with epilepsy is 
evident from an early age, and this is important for health personnel to be aware of in 
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The International League Against Epilepsy (ILAE) defined epilepsy in 2014 as (1):  
 
 
In this definition, there is a variety of different expressions of epileptic seizures. 
Classification and descriptions of seizures have therefore been of importance through 
history, and in 2017 ILAE proposed an updated version of “Operational classification 
of seizure types” (2). As seen in Figure 1 the classification separates focal, 
generalized and unknown onset as the main seizure characteristics. In focal onset 
seizure a description of awareness is considered next, and then motor- and nonmotor 
onset of seizure. Generalized onset epilepsy classifies further as motor or non-motor, 




Figure 1: Based on “Operational classification of seizure types by the International 
League Against Epilepsy.” (2) 
As well as a definition of epileptic seizures, there is of importance to classify epilepsy 
types. Throughout the 20th century the topic of epilepsy classification has sparked 
intense debate, and the ILAE have updated their terminology several times. In 1989 a 
revised version of classification of epilepsies and epileptic syndromes was authored 
(3) and this version has been highly influential worldwide and has had a major impact 
on epilepsy care and research (4). With time and further knowledge the ILAE felt the 
need to revise the classification of epilepsies and in 2017 ILAE classification of the 
epilepsies position paper of the ILAE commission for calssification and terminology 





In this new classifiaction there is three levels (figure 2). The first level contains 
information about seizure type, which thoroughly discussed in a separate paper (2), 
and this is discussed above and in figure 1.  
The second level discusses epilepsy types, and contains four categories, 1) 
generalized, 2) focal, 3) combined general and focal, and 4) unknown. This level 
assumes that a patient has a diagnosis of epilepsy based on the current definition. A 
generalized epilepsy is made on clinical charachteristics, but would typically be 
supported by an electroencephalography (EEG) of generalized spike-slow wave 
pattern (4). Focal epilepsy include a range of seizure types, with and without impaired 
awareness, both motor and non-motor symptoms. This diagnosis is also based on 
clinical grounds, but supported by interictal epileptic acitivity in EEG. Patients with 
both focal and generalized seizures fits into the new group of combined generalized 
and focal epilepsies. The unknown category is used where a diagnosis of epilepsy has 
been concluded, but the physician is unable to determine whether it is a focal or 
generalized epilepsy due to insufficient information. 
Epilepsy syndromes are labeled in level three. This refers to a cluster of symptomes 
containing seizure types, EEG and imaging features that occur together (4). 
To determine the etiology of epileptic seizures is of great importance and this 
typically includes neuroimaging to determine structural pathology. There are five 
other etiological groups: Genetic, infectious, metabolic, immune and unknown. 
The final perspective to be considered in epilepsy classification and terminology is 
comorbidity. Many epilepsies are associated with a range of comorbidities including 
intellectual disability, psychiatric challenges such as autism spectrum disorder, 
depression, and anxiety, as well as psychosocial concerns (4). Comorbidity will be 
covered extensively in this dissertation. 
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Figure 2: Framework for Classification of the Epilepsies, based on (4). *discussed in 
figure 1. 
1.2 Epidemiology 
Epilepsy is a common disorder in both children and adults. Population-based studies 
have shown incidence-rates in childhood to range from 0,5-8 per 1000 person-years 
(5-7), with a peak incidence within the first months of infancy. In adults the incidence 
rate of new-onset epilepsy varies with age, especially rising with every decade over 
60 years (6). In a Norwegian review of prevalence and incidence in Nordic countries 
it was assumed that the incidence of new cases per 100.000 person-years was 30-60 
(8), whereas the prevalence of active epilepsy was estimated to 0,6% (8). The 
prevalence of epilepsy varies in different parts of the world, with a marked difference 
between developed and non-developed countries. A review from China estimated a 
prevalence of 0,3% (9), and a study from Nigeria found a prevalence of 2,1% in rural 
communities and 0,5% in semirural communities (10). 
In pregnant WWE, 0.5% used antiepileptic drugs 3 months before conception in 





paper from 2015 reports that 0.51% of study-participants (n=1.248.713) were 
prescribed an AED during pregnancy, ranging from 0.43% to 0.60% depending of 
residing country (12) 
1.3 Psychiatric comorbidity and stigma 
Multiple epidemiological studies show an increased risk of psychiatric comorbidity in 
people with epilepsy, both in adulthood and in youth (13-18). Children with epilepsy 
have been found to have an increased risk of psychiatric comorbidity such as 
depression(19), anxiety(19), attention deficit(19) and hyperactivity disorder (ADHD) 
(19) and autism spectrum disorder (19) compared with children without epilepsy. This 
has been found in uncomplicated epilepsies, but is especially increased in complicated 
epilepsies. Complicated epilepsy is defined as: Epilepsy plus brain lesions resulting in 
impaired cognitive function (13, 20). Likewise is mental health issues more prevalent 
in adults with epilepsy, with increased risk of depression (16, 21, 22), anxiety (17, 18, 
21), ADHD(21), cognitive impairment (23) and eating disorders (17, 24). In trying to 
understand the increased burden of psychiatric comorbidity in epilepsy, a theoretical 
framework of mediators have been proposed (20) (figure 3). Mediators include core 
epileptic characteristics such as early onset of seizures, duration of epilepsy, seizure 
drugs, and frequency and duration of seizures. Other potential mediators include 
epilepsy syndromes, underlying brain disorders and brain development and ageing, in 
addition to influences such as genotypic, psychological and sociocultural influences. 
This shows that increased psychiatric comorbidity in epilepsy is a multifaceted 
challenge, and few treatment options aside for seizure drug management and 




Figure 3, based on Uncovering the neurobehavioural comorbidities of epilepsy over 
the lifespan (20) 
1.3.1 Stigma 
Historically, but also today, considerable stigma has been attached to people with 
epilepsy. Stigma is defined as a negative reaction by other to an attribute of a person 
that serves to spoil one’s own social identity (25). Along with comorbidity and the 
seizures, stigma adds up to the total burden of epilepsy. Less social support, impaired 
social identity, humiliation and discrimination may be results of the stigma attached to 
epilepsy (25), which in turn leads to further social and economic morbidity and has 
the trademarks of a vicious cycle that is hard to interrupt. Few studies have studied 
the results of intervention with the purpose of reducing stigma, but it is widely agreed 
that public information and education is necessary (25). In 2008 a study from 
Germany compared public opinion of epilepsy through the 20th century and into the 
21st century, using results from surveys who have been conducted five times since 
1967 (26). Negative attitudes of epilepsy decreased in 2008 compared to 1967, with 
18% in 2008 objecting to having a son or daughter marrying a person with epilepsy 





employed like other people, compared to 31% in 1967. In 1967 27% thought epilepsy 
was a form of insanity. This has decreased in 2008, but still 11% of persons asked 
thought epilepsy was a form of insanity. This perhaps illustrates stigma in epilepsy, 
which otherwise often can be hard to define or measure (26). 
1.3.2 Treatment of psychiatric comorbidity 
As psychiatric comorbidity are more frequent in people with epilepsy, focus must be 
on treating this in the same way as in the general population, if not better. Previously 
there has been a reluctance to prescribe antidepressants or anxiolytica to people with 
epilepsy, possibly due to fears over negative influence on seizure threshold. Hospital 
based studies from the 1980s and 1990s using high doses of tricyclic antidepressants 
raised questions of seizure induction (27-29). Follow-up studies in out-clinic patients 
did not support these concerns, but the idea persisted. This limited treatment within 
this group, and impairing quality- of-life (30). Later, antidepressants have been found 
to be anticonvulsive when investigated as a group (31). It is therefore of great 
importance that health personnel treating people with epilepsy is aware of this 
common misperception, and that people with epilepsy must be given the right 
medication when needed (32). 
1.4 Pregnancy and offspring 
1.4.1 Seizures in pregnancy 
Most WWE have normal pregnancies and deliveries, but the threat of seizures during 
pregnancy and the effects seizures may cause on the foetus are of great concern to 
many. In terms of seizures it is the generalized tonic clonic seizures (GTCS) that are 
most feared. Seizure during labour is rare, but two case studies have shown 
bradycardia and asphyxiation in the foetus after a GTCS during labour (33). Seizures 
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during pregnancy have been associated with a significant higher preterm risk, a 
shorter gestational age, and a reduced birth weight (34, 35). In this study from 
Rauchenbach et al the 106 pregnant WWE also used antiepileptic drugs (AED) which 
are regarded as a confounding factor (34). Indications also point towards frequent 
seizures during pregnancy have a detrimental effect on neurodevelopment in the 
developing foetus (36). One study investigated 240 children born of mothers with 
epilepsy of 6 years or older. Of these, 80 children were born of mothers who did not 
use AEDs during pregnancy. Adab et al found that five or more GTCS during 
pregnancy was an independently risk factor for low IQ in the offspring (37). Studies 
with animal-models have found similar results. Novaes et al induced seizures in 
pregnant rats, and the offspring displayed impaired social behaviour (38), whereas 
Vale and coworkers found an effect on hippocampal interneurons in rat-pups with 
mothers who had seizures during pregnancy, as well as deficits in motor coordination 
and more immobility (39). 
Status epilepticus is rare during pregnancy, in the large EURAP study there were 10 
cases of convulsive status epilepticus of 3784 pregnancies reported (0,26%). Of these, 
there was one stillbirth and three children had major congenital malformations. 
1.4.2 Maternal mortality 
The increased risk of life-threatening pregnancy complications such as seizures, 
preeclampsia, and excessive bleeding postpartum, give rise to the thought of 
increased maternal mortality within the epilepsy population. In fact, two independent 
studies have shown a more than 10-fold increased mortality-rate for WWE compared 
to the general population (37, 40). Considering that the standard mortality rate is 2-3 
times increased in people with epilepsy throughout life, shows that WWE is especially 
vulnerable during and after pregnancy (37). It is hypothesized that in addition to the 
aforementioned risk factors seizures, preeclampsia and postpartum bleeding, another 





epilepsy (SUDEP) (40). Sudden unexpected death is more than 20 times as common 
in people with epilepsy compared to the general population (41). 
1.4.3 Complications during pregnancy 
Regardless of seizure frequency, WWE have an increased risk of complications 
during pregnancy and delivery. Borthen and coworkers, using the MBRN, found that 
WWE had an increased risk of mild pre-eclampsia and preterm birth compared to 
women without epilepsy (42). Further, WWE and AED use had an increased risk of 
gestational hypertension and vaginal bleeding late in pregnancy (42). This was 
consolidated in a hospital-based study from the same research group where 205 
consecutive deliveries at Haukeland University hospital with a confirmed diagnosis of 
epilepsy were retrospectively investigated and compared to 205 women without 
epilepsy with similar age and parity. WWE and AED use had an increased risk of 
severe preeclampsia and early vaginal bleeding (43). A systematic review published 
in the Lancet in 2015 where 38 papers and more than 2,8 million pregnancies were 
considered, there was an association between maternal epilepsy diagnosis and adverse 
maternal outcome such as spontaneous miscarriage, antepartum haemorrhage, 
postpartum haemorrhage, induction of labour, caesarean section, preterm birth and 
hypertensive disorders (44). Risk of adverse delivery outcome such as caesarean 
section, increased postpartum bleeding and low Apgar score was also found to be 
increased in WWE in Borthen and coworkers’ investigation using the MBRN (45). 
In relation to pregnancy and delivery, depression and anxiety are also complicating 
factors. Bjørk et al found in 2015 an increased risk of both in WWE using the 
Norwegian Mother and Child Cohort Study (MoBa) (46). They also found that the 
recovery rate was lower three years after delivery in WWE, and stresses the idea that 
it is important to identify patients at risk before delivery as symptoms of depression 
may be undertreated in this group. 
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Outcome of pregnancy in WWE does not only concern mothers, but the offspring as 
well. Questions have been raised in terms of how epilepsy influence development in 
the womb, but also long term effects such as cognitive effects in children born to 
mothers with epilepsy.  
Veiby and coworkers found in 2013 that exposure to antiepileptic drugs during 
pregnancy was associated with impaired motor skills at the age of 6 months using the 
Norwegian Mother and Child cohort study (47). Use of multiple antiepileptic drugs 
was associated with worse outcome in children, both in terms of fine motor skills, but 
also in social skills, compared to infants with no such exposure. In this study, 
breastfeeding of the infant was not associated with harmful effects (47). 
We have continued to study social skills and cognitive performance using the 
Norwegian Mother and Child cohort study, which in its prospective design enables 
researchers to follow children born of mothers with epilepsy. Veiby et al found an 
increased risk of autistic traits in children exposed to antiepileptic drugs in utero. The 
children were investigated at 18 months and 36 months of age (48). This has also 
consistently been found in other studies (49-51). What Bjørk et al were able to 
establish through a combination of self-reported information of use of folic acid 
preconceptionally and during pregnancy, and serumlevels of folic acid in gestational 
week 18-20, was that folic acid supplementation reduces the risk of autistic traits, 
especially in women using antiepileptic drugs (52). This shows that diet is of 
significance in pregnancy for WWE. 
Studying verbal skills in children born to mothers with epilepsy in the Norwegian 
Mother and Child cohort study, Husebye et al found that AED-exposed children had a 
language delay compared to non-exposed children at 18 months and 36 months of age 
(53). Also in regards to development of language skills, folic acid supplementation 






1.4.4 Pregnancy registries 
Internationally there are three major population-based registries containing 
information about AED exposure, pregnancy- and infant outcome from the Northern 
hemisphere. These are the UK Epilepsy and Pregnancy register, the North American 
AED Pregnancy Registry, and European and International Registry of Antiepileptic 
Drugs in Pregnancy. They were all established in the late 1990s, where the UK 
register were the first to establish in 1997. The overall aims are similar for all three 
registries; to determine the risk of MCM in pregnancies exposed to prenatal use of 
AEDs (54), but there are some differences in methodology. These differences in 
methodology have made it difficult to merge or harmonize the different registries 
(54). The latest updates show that 5206 cases were included in the UK register (55), 
9818 AED exposed women were included in NAAPR (56), and in EURAP 21.875 
pregnancies were included in 2016 (57). 
In Scandinavia, there is a good foundation for epidemiologic studies concerning 
pregnancy and birth, as all Scandinavian countries have national birth registries (58-
60). This is a vast source of information, especially with its unique design of 
compulsory inclusion which will diminish selection bias in example. 
All these registries have added invaluable knowledge about a wide range of issues 
concerning maternal health, and especially knowledge about outcome for pregnancies 
in WWE.  
1.5 Treatment of epilepsy and anti-epileptic medication 
1.5.1 Antiepileptic drugs 
The overall idea in treating epilepsy is to prevent the occurrence of seizures. This is 
generally obtained in approximately 70% of cases when applying an antiepileptic drug 
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(61). Antiepileptic drugs are either classified by mechanism of action, or by efficacy 
spectrum. Because different drugs have different mechanisms of action and different 
efficacy spectrums, it is important to take into account seizure type, syndrome and 
other characteristics of the individual patient to be able to find the ideal antiepileptic 
drug. 
Efficacy spectrum and choice of antiepileptic drug 
The International League Against Epilepsy (ILAE) formed in 2006 guidelines for 
treatment with antiepileptic drugs by performing a structured literature review (62). 
These guidelines were updated in 2013 (63). Norwegian guidelines for treating 
epilepsy are based on these international reviews (64). When reviewing the literature 
the authors realized that many of the studies had major flaws, leading to poor 
documented effects of antiepileptic drugs, especially in generalized seizures in adults, 
and in treatment of epilepsy in children (62). When choosing an antiepileptic drug in 
treatment of epilepsy it is important to weigh potential anti-epileptic effect vs 
potential adverse effect on an individualistic basis (62). 
Treatment for focal onset seizures 
There is four drugs with evidence level A, which means the effect of this drug is well 
established. Carbamazepine, levetiracetam, phenytoin and zonisamide have level A 
evidence of efficacy. Valproate have level B evidence, as effectiveness is regarded as 
probable in partial onset epilepsy. Gabapentin, lamotrigine, oxcarbazepine, 
phenobarbital, topiramate, and vigabatrin have level C evidence, as they have a 
possible effect (63). When taking documentation for effectiveness in to account, and 
weighing up possible adverse effects, Norwegian guidelines states oxcarbazepine, 
lamotrigine and levetiracetam as drugs of choice for focal onset epilepsy. 
Treatment for generalized onset seizure 
For this group there is less documented effect, due to lower quality of clinical trials. 
Carbamazepine, lamotrigine, oxcarbazepine, phenobarbital, topiramate and valproate 





regarded as having a potential effect (63). Norwegian guidelines states valproate as 
the drug of choice in general onset epilepsy, the one exception being fertile women. 
Second line of choice is levetiracetam, lamotrigine and topiramate (65). 
Ethosuximide and valproate is effective against absence seizures (40, 63, 64). 
1.5.2 Antiepileptic drug treatment during pregnancy 
The association of major malformations in the offspring of mothers using 
antiepileptic drugs have had a growing awareness during the 20th century, which led 
to the EURAP epilepsy and other pregnancy registries. This is a cohort from 42 
countries that prospectively monitor pregnancies exposed to monotherapy of 
antiepileptic drugs and in 2011 a paper comparing four different drugs (lamotrigine, 
carbamazepine, valproate, and phenobarbital) was published. Comparatively a low 
dose of lamotrigine had the lowest rates of major malformations in the offspring, 
whereas risks of malformations were significantly higher with valproic acid and 
phenobarbital, as well as higher doses of carbamazepine (66). A dose-dependency 
was seen for all four drugs. I 2016 a new paper was published from EURAP, now the 
cohort contained 7355 pregnancies exposed to antiepileptic drugs, and Tomson et al 
were able to compare eight different drugs (carbamazepine, lamotrigine, 
levetiracetam, oxcarbazepine, phenobarbital, phenytoin, topiramate, and valproate) 
(57). Again valproate and phenobarbital had the highest risk of malformations (10.3% 
and 6.5% of pregnancies respectively), and lamotrigine and levetiracetam were 
considered the safest options (2.9% and 2.8% respectively) (57). 
Other pregnancy registries such as the North American AED Pregnancy Registry 
(NAAPR) and the UK Epilepsy and Pregnancy register have found similar results. 
Valproate and phenobarbital carries the significantly highest risk of major congenital 
malformations, whereas newer drugs such as lamotrigine and levetiracetam are safer 
options (55, 67, 68). It is stressed that even though lamotrigine has been found to be a 
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safe option in terms of MCM, seizure control is of great importance, and lamotrigine 
can in some cases be less effective compared to other antiepileptic drugs such as 
valproate (55). 
A paper from the EURAP-study shows that seizure-control is reduced when valproate 
is withdrawn during pregnancy (69). 
AED in monotherapy have been shown to have similar risk of intrauterine death and 
there has been shown no dose dependency, although Tomson et al found that 
polytherapy increased this risk; RR 1.4 (CI 1.1-1.7) compared to all monotherapies 
(70).  
1.5.3 Unintended pregnancy 
AEDs and hormonal contraceptions have a high risk of bidirectional interaction, and 
that decreases seizure control and failed contraceptive function may be a consequence 
(71). Failed contraceptive medication is an apparent reason for unplanned pregnancy, 
and one study found that one in four unplanned pregnancy in WWE was due to failed 
contraception. Also less than 55% of WWE had planned their pregnancy (72). 
1.5.4  Catamenial epilepsy 
Some women have increased seizure activity in relation to hormonal changes 
following the menstrual cycle. Typically clusters of seizures occur in the ovulatory 
and menses fase of the menstrual cycle. This is called catamenial epilepsy. It does not 
refer to a specific type of epilepsy, but to the rhythmicity in seizure occurrence. In 
addition to antiepileptic treatment as described in the previous chapter, treatment 
focuses on influencing hormonal changes with oral contraceptives (73). 
Contraceptives with progesterone are most frequently used, but also acetazolamide 





1.5.5 Other antiepileptic treatment 
Surgical treatment 
Surgery includes resection or destruction of parts of the brain with epileptic origin. 
Surgical treatment is an option to patients with drug-resistant focal epilepsy (40). 
Neurostimulation 
The most common mode of treatment with use of neurostimulation, is vagus nerve 
stimulation. Originally, vagus nerve stimulation was developed for patients with drug-
resistant epilepsy who were not candidates for surgical treatment. Half of patients 
with vagus nerve stimulation reduces seizure frequency by 50% (74), although only 
5% become seizure-free. 
Ketogenic diet 
Ketogenic diet is a well-established and well-documented mode of treatment of 
epilepsy in children (75), but there is less documentation in adults. In a small sized 
study from Norway four patients out of six with juvenile myoclonic epilepsy had 
>50% seizure reduction with the less restrictive modified Atkins diet (75). The 
modified Atkins diet restricts intake of carbohydrates to 15-20 g a day, and 
encourages food with a high fat content. 
1.6 Epilepsy in youth 
Epilepsy is the most common neurological disorder in youth with prevalence numbers 
varying between 0.05-1 % (76). Among offspring in the MoBa cohort the incidence 
rates during the first year 144 per 100.000 person-years, and 58 per 100.000 person-
years when considering ages 1 to 10 years (5). In total 587 of 112.744 (0.5%) met the 
criteria for validated epilepsy-diagnosis. 
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1.6.1 Etiology 
The underlying cause of epilepsy in youth are generally divided in to three categories, 
namely genetic, metabolic/structural and unknown (77).  
Genetic causes 
The idea of genetic epilepsy is that the disease is exclusively caused by mutations in 
the genome without environmental impact (77). Most types of genetic epilepsies 
begin in childhood and include childhood absence epilepsy, juvenile absence epilepsy, 
juvenile myoclonic epilepsy, as well as more severe syndromes with often therapy 
resistant seizures such as Dravet syndrome and West syndrome. 
Metabolic/structural causes 
Almost any structural lesion or damage to the cerebral cortex can cause seizures and 
epilepsy. Metabolic disturbances such as high fever, hyponatremia, and hypocalcemia 
are perhaps the most common causes of seizures in youth. Ischemia perinatally, or 
later in life, head trauma, infections such as meningitis or encephalitis are all common 
disorders that can cause lesions with epileptic potential. 
Unknown causes 
In defining epilepsy etiology this category reflects the fact our knowledge in certain 
cases are limited, and we’re not able to determine the exact cause (77). 
1.6.2 Comorbidity 
Psychiatric comorbidity is quite frequent in children and adolescents with epilepsy. 
Various studies have estimated that 21-60% of children with epilepsy have comorbid 
depression or anxiety (76). This is up to six times more than the general population, 
and also considerably higher than other children with chronic disease. Also children 
with complicated epilepsy have more comorbid psychopathology than children with 
uncomplicated epilepsy (76). There is thought to be multiple factors contributing to 





dysfunction, male gender, and early onset epilepsy were seen as risk factors in a study 
from Norway (78). Sleep disorders have also elevates the risk in paediatric epilepsy 
compared to population-based data, and are especially elevated among those with 
comorbid psycopathology (79) 
1.6.3 Cognition and education 
A global cognitive impairment is more common in children and adolescents with 
epilepsy than in their peers in population based studies, and rates of intellectual 
disability range from 21-40% (80). This will lead to difficulties in school 
performance, and this is also reflected in the fact that more children with epilepsy 
receives special educational services (81, 82). Global cognitive difficulties are seen as 
the main contributor to a significant lower academic achievement among people with 
epilepsy. Adjusted for IQ, other factors such as early onset epilepsy, difficulties in 
school attendance and specific cognitive deficits are also seen as risk factors for lower 
academic achievement (80). In the literature there is a separation between low-
achievement due to global cognitive impairment, and underachievement that is 
discrepant to IQ-levels. Youth with epilepsy are comparatively more prevalent in both 
categories (80). Early screening for educational difficulties is imperative for positive 
outcome, especially in cases where the academic underachievement is discrepant to 
IQ-levels (80). 
1.6.4 Social aspects 
Whatever reason for lower educational levels, inevitably this will have socioeconomic 
consequences. In the UK there is a strong correlation between epilepsy and living in 
socioeconomic deprived areas (83), and in Iceland low socioeconomic status was a 
risk factor for epilepsy (84). Low income and higher rates of unemployment are also 
features associated with persons with epilepsy (85). People with symptomatic epilepsy 
are less likely to have a partner and offspring than the referent (86, 87), and compared 
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to normal population there is a higher risk of being unfit to work (87). As well as 
lower socioeconomic status, persons with epilepsy are more likely to report reduced 
quality of life and emotional problems (85). Because of stigma, previously mentioned 
in chapter 1.3.1., there is a risk for social isolation and thus less possibilities of social 
interaction and building relationships (88). 
1.7 Overweight 
Worldwide overweight and obesity is a growing concern as prevalences continue to 
increase in adults (89), and overweight also increases in youth (90). In the US, more 
than 35% of adults were obese (BMI >30) in 2010, and almost 17% of youth (91).  
Overweight and obesity represent huge and growing public health issue, with it being 
an essential risk factor for cardiovascular disease, type 2 diabetes and some cancers 
(92). Figure 4 illustrates how weightgain in kg increases the risk of disease, in 
example an increase of 5-8 kg increases the risk of type 2 diabetes with 100% (92) 
(figure 4). 







1.7.1 Epilepsy and overweight 
Overweight and obesity is thought to be common in people with epilepsy, and in an 
adult US population they found that 55.2% of people with epilepsy was overweight, 
similar to the general US population (93). 
Another study found that overweight people with epilepsy reported a poorer health 
compared to the general population in a study from Georgia and Tennessee. They also 
reported a lower family income and lower employment rates (94). People with 
epilepsy reported a higher rate of obesity and the authors highlights the need for 
further studies that examines the physiological and psychosocial interactions between 
epilepsy and overweight. 
Overweight in general is a growing concern in the industrialized world, but also in 
some developing countries. In Norway, overweight has been scarcely studied in 
people with epilepsy. 
1.7.2 Mechanisms for increased overweight in epilepsy 
There are several possible mechanisms for increased overweight in epilepsy. Both 
structural, iatrogenic and social/environmental theories are suggested. 
Silveira and coworkers showed that amygdaloid seizures activate hypothalamic nuclei 
that are prominently involved in reproductive function and reproductive endocrine 
secretion and this could explain clinical features such as PCOS and hypothalamic 
amenorrhea (95). Hypothalamic nuclei are also involved in feeding behavior (96). 
Feeding behavior could then be affected by seizures in the same way endocrine 
function is affected by hypothalamic neuroendocrine control of energy homeostasis 
(93). 
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One study in Canada studied children and adolescents with epilepsy in terms of 
physical activity and overweight. There were 79 young people with at least 3 months 
history of epilepsy compared to their siblings (n=99). Those with epilepsy were more 
likely to be overweight and were less active (97). A German study investigated social 
and physical activity in 136 people with epilepsy (98). They were significantly less 
active in regular sports activities than controls, and they also judged sports to be more 
dangerous than controls. Furthermore, in a clinical study, people with epilepsy had a 
significantly higher BMI than controls, as well as having less aerobic and muscle 
strength endurance (98). Other studies supports this (65, 98), and as people with 
epilepsy tend to be less physically active this leads to increased BMI, decreased 
aerobic endurance, poorer self-esteem, and higher levels of depression and anxiety 
(99). 
Ben Menachem writes that the two most important factors for weight gain in people 
with epilepsy is social factors and use of antiepileptic drugs (AEDs) (92). 
Furthermore there is known weight inducers such as valproate, carbamazepine and 
pregabalin, weight neutral AEDs include lamotrigine, gabapentin, pregabalin, 
vigabatrin and levetiracetam, whereas AEDs associated with weight loss include 
topiramate, zonisamide and felbamate (92). 
1.7.3 Consequences 
Obesity is a well-established risk factor for complications during pregnancy, such as 
preeclampsia and other hypertensive disorders(100-102), diabetes type 2(103, 104), 
miscarriage(105), caesarian delivery (106, 107) and induction of labour (108, 109). 
The review of epilepsy in pregnancy published in Lancet had no mention of 
overweight or obesity in relation to pregnant WWE (44). This reflects that obesity is 
scarcely investigated in WWE, especially in relation to pregnancy and its outcome. 
As overweight is a known risk factor for numerous adverse health effects in the 





epilepsy. To what degree is overweight a health issue in people with epilepsy, and 
how does overweight influence comorbidity in people with epilepsy? 
1.8 Eating disorders 
Eating disorders have increased dramatically in frequency in the last 50-60 years, and 
did not pose a severe challenge until the late 1970s (110). Thus research on the 
subject was scarce, and before year 2000 there only existed papers from small clinical 
samples (111). The most common eating disorders are anorexia nervosa (AN), 
bulimia nervosa (BN) and binge eating disorder (BED), in which life-time prevalence 
in Norway is 8.7% , and which will be prevalent in 3.8% of the population at any time 
(111, 112). In the Norwegian Mother and Child cohort there is a prevalence of 
approximately 5% of eating disorders (113). Rai et al. described an increased rate of 
self-reported eating disorders in people with epilepsy compared to the general 
population (17), and Reiter et al. also found an increased rate of eating disorders in 
pregnant WWE compared to other pregnant women (24). However, the prevalence of 
eating disorders in people with epilepsy have been scarcely studied, and there is a 
need for further investigations. 
1.8.1 Etiology 
The etiology of eating disorders are largely unknown, but factors such as body 
dissatisfaction, depression or anxiety and low self-esteem seem to be precursors 
(110). Interpersonal experiences that have been most frequently associated as risk 
factors for eating disorders are abuse, trauma and teasing (110), although there is still 
some debate into what mechanisms play a part and to what degree these are prominent 
in developing and maintaining an eating disorder (110). A theory is that a central 
feature in anorexia nervosa is personality traits such as having an extreme need to 
control eating, but also to control other aspects in life (114). Other contributing 
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factors is sociocultural pressure to be thin, family influences, dieting, biological 
contributors and genetic predisposition(110). BED in pregnancy has also been found 
to be associated with lifetime sexual abuse, anxiety and depression (115). 
1.8.2 Consequences 
Eating disorders may influence birth and obstetric outcomes, similarly to epilepsy and 
overweight. A Finnish population-based register study compared women with eating 
disorders to referent women and found that women with AN and BN had significantly 
lower weight babies, whereas women with BED had higher weight babies (116). AN 
was also associated with premature birth and perinatal death, and women with BN 
had increased risk of babies with low Apgar score. Using the Norwegian Mother and 
Child cohort study, Bulik et al found that women with BED had higher weight babies, 
a higher risk of large for gestational age babies and caesarian section than the referent 
(117). The authors noted in this paper that the statistical power for the lower prevalent 
disorders such as AN and BN was inadequate to determine an association to adverse 
obstetric outcomes. As noted in chapter 1.8. the prevalence of eating disorders in 
people with epilepsy is largely unknown. The influence of eating disorders on 
outcome of pregnancy and delivery in WWE is also largely unknown and studies on 
this subject is needed. 
1.8.3 Diagnostic criteria 
The American Psychiatric Association’s diagnostic manual of mental disorders, 4th 
edition (DSM-IV), was the most common diagnostic tool in which to classify mental 
disorders, and in example eating disorders. Figure 5 shows the diagnostic criteria of 
anorexia nervosa (AN), bulimia nervosa (BN), eating disorder not otherwise specified 






Figure 5: Diagnostic criteria for eating disorders in DSM-IV. 
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2. Aims 
Our main aim in this thesis was to determine how overweight and eating behavior are 
distributed in people with epilepsy, and whether findings were consistent when 
examining different study-populations. We also wanted to investigate predictors and 
consequences of overweight and eating disorders. 
Paper 1: To determine the prevalence of eating disorders in pregnant WWE. Further, 
we wanted to examine how eating disorders influence pregnancies in WWE. 
Paper 2: To determine whether WWE are more overweight than other women, and to 
investigate the effects of, and interactions between, overweight and epilepsy 
combined on pregnancy and obstetric outcome. 
Paper 3: Finally, we aimed to study whether youth with epilepsy are more overweight, 
have an increased risk of eating disorders, and to determine quality of diet compared 








3.1 The Norwegian Mother and Child Cohort Study. 
3.1.1 Data material 
The Norwegian Mother and Child Cohort Study (MoBa) is a prospective population-
based study, which recruited pregnant women in Norway from 1999 to 2008. The 
objective of Moba was to test specific aetiological hypotheses by estimating the 
association between exposures and diseases, aiming at prevention (118). It included 
more than 100.000 women and information about their pregnancies, general health 
and social situation was gathered through comprehensive questionnaires. Pregnant 
women from all over Norway were invited to participate prior to a scheduled 
ultrasound examination in gestational week 18-20. The first questionnaires were sent 
to participants in week 13-17 (Q1). Follow-up questionnaires were sent in gestational 
week 22 (Q2) and 30 (Q3). Thereafter questionnaires were sent 6 months (Q4), 18 
months (Q5), 36 months (Q6), 5 years (Q-5year), 6 years (Q-6year), 7 years (Q-7year) 
and 8 years (Q-8year) after delivery. It is planned to follow the cohort further, and 
questionnaires are still being gathered. The recruitment included 50 of Norway’s 52 
hospitals with maternity units, and the overall response rate was 41% (119). In paper 
1 and 2 questions from Q1 and Q4 were used. In our version of the MoBa cohort there 
were totally 106.508 pregnancies, whereas 706 reported having epilepsy for paper 1. 
For paper 2, the cohort was updated and now contained in total 107.516 pregnancies, 
with 713 cases of pregnancies with reported maternal epilepsy. 
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3.1.2 Medical Birth Registry of Norway 
MBRN is a compulsory registry for all pregnancies and deliveries in Norway. The 
registry was established in 1967 and is run by the Norwegian Institute of Public 
Health (120). Midwives and general practitioners register information about maternal 
health during pregnancy, as well as birth outcome. The register is linked to the 
National Population Register to ensure a complete registration of all births in Norway. 
MBRN is linked to MoBa through an anonymous code, and we were therefore able to 
gain supplementary information about maternal health and birth outcome.  
3.1.3 Variables and outcomes 
The diagnosis of epilepsy was self-reported in MoBa, where participants answered 
yes or no to a question of whether they have or have had epilepsy. AED use was 
defined through three pathways:  
1) Reported AED use in MoBa through a predefined yes/no question in MoBa 
2) Or having reported an epilepsy diagnosis in MoBa and provided information 
about AED use in free-text answer 
3) Or reported diagnosis of epilepsy in both MoBa and MBRN, and a registered 
use of AED in MBRN. 
MoBa questionnaires were made in accordance with DSM-IV criteria for eating 
disorders. When trying to comply with the diagnostic criteria of eating disorders in 
paper 1, there were some adjustments that were needed. For AN the fourth criteria 
concerning amenorrhea had to be removed due to the fact MoBa consists of pregnant 
women. This criterion has also been removed in the new version of the manual – 
DSM-V. In the EDNOS category we focused on criterion 2, which was called 
impaired bodyimage and AN criteria are met except low BMI and amenorrhea, and 





In paper 1 we investigated associations between maternal epilepsy and ED, and how 
this influenced pregnancies in terms of hypertension, diabetes, preeclampsia, 
caesarian section, peripartum depression and/or anxiety (22), weight gain during 
pregnancy, SGA (121), LGA (121) and ponderal index. In paper 2 associations 
between maternal epilepsy and overweight, and how this influenced outcome in 
pregnancy for the same variables as in paper 1. 
Overweight was defined as body mass index (BMI = weight/height2) > 25, and 
obesity as BMI > 30. 
3.2 Health Profile for Children and Youth in Akershus 
Study 
3.2.1 Data material 
Health Profile for Children and Youth in Akershus Study is a cross-sectional 
population based study (122). The study was conducted by the Norwegian Health 
Services Research Centre in 2002. School classes from all municipalities in Akershus 
County were randomly selected, and all pupils aged 13-19 years in the chosen classes 
were invited to participate. Parents were informed and had to give their written 
consent. Questionnaires containing 110 questions regarding main topics such as: 
sociodemographic conditions, social network and school, smoking, alcohol, drug 
abuse, nutrition and attitude concerning body, physical health, psychosocial health, 
mental health, use of health services(14). The questionnaires were completed during a 
classroom session and were all anonymous. As many as 19.995 adolescents answered, 
yielding an 85 % response rate. 
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3.2.2 Variables and outcomes 
The participants had the opportunity to report a diagnosis of epilepsy and this defined 
the epilepsy group. This question could be answered by “yes”, “no” or “don’t know”. 
The answer “yes” counted as having epilepsy and “no” and “don’t know” counted as 
not having epilepsy. A total of 247 individuals (1.2%) reported a diagnosis of 
epilepsy. All other participants constructed the reference group (n=19.748). 
Individuals reporting a diagnosis of asthma formed a control group of chronic disease 
(n=3.320), participants with asthma were also included in the reference group. 
Participants reported if they had been in contact with school nurse or other health 
personnel regarding eating disorders and this defined eating disorders in this cohort. 
Before conducting the study, an unhealthy diet was defined by a group of nutritionists 
as eating or drinking candy, potato chips, French fries, or sugar containing soda daily. 
We constructed a dichotomous variable of physical activity where the cut-off was set 
at being physically active two or more times a week. Participants reported if they were 
currently on a diet or had been in the past. Mean age of menarche was calculated for 
female participants. We calculated BMI with the help of an age adjusted scale from 
the World Health Organization (123). 
3.3 Statistics 
3.3.1 Statistical methods 
When computing data we used IBM SPSS Statistics version 21. We studied 
differences between groups using Student’s t-test and Pearson’s chi-square test. 
Comparable groups were tested for variance using either Q-plotting or Levenes test. 
With an expected count of any cross-table was under 5, we used Fisher’s exact test. P-
values of < 0.05 were considered statistically significant. To estimate the odds ratios 
(OR) with 95% confidence interval (CI) we used binary logistic regression. Using this 





smoking, and socioeconomic factors (low household income, low education, and/or 
being a single mother) in paper 1 and 2. In paper 3 we were able to adjust for reported 
low family income and living with a single parent. 
3.3.2 Additive and synergistic effects 
By introducing an interaction term to the regression model in paper 2 we investigated 
whether there was a potentiating effect of epilepsy and overweight on complications 
during pregnancy or delivery. Potentiating effect was defined as an increased effect 
compared to the expected cumulative risk of two factors, whereas additive effect was 
defined as epilepsy and overweight having an independent and cumulative effect on 
risk estimates. We compared groups of 1) WWE + overweight to normalweight WWE 
and 2) WWE + overweight to overweight women without epilepsy. When both 
comparisons were statistically significant we regarded the effect as an additive risk. 
To determine potentiating risk, an interaction term was inserted as a variable, 
multiplying epilepsy x overweight. If the interaction variable was significant in the 
regression model, we regarded the effect as potentiating. 
3.4 Ethics 
The MoBa study was approved by the Regional Ethics Committee (REK nr 
2011/1616), this was also the case for Health Profile for Children and Youth in 
Akershus study (REK ref. 40-02022). Participants were included by informed 
consent, inclusion was voluntary and data was anonymous to researchers. Participants 
had the option of study-withdrawal at any time. In publishing information of adverse 
risk factors, there is a potential for stigmatization of WWE. These factors were 
considered when discussing cost vs benefit, and we conclude that the benefits of 
further knowledge in this field outweigh the possible negative implications. Further 
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awareness of risk factors concerning overweight and eating disorders in people with 






4.1 Paper I 
In our first paper, Epilepsy and eating disorders during pregnancy: Prevalence, 
complications and birth outcome, we found that WWE had a significantly increased 
rate of BED during pregnancy (6.5% vs. 4.7%, p<0.05) and impaired bodyimage 
(6.1% vs. 3.6%, p<0.05) compared to the referent. We found no differences between 
groups in terms of rates of anorexia nervosa or bulimia nervosa. WWE and comorbid 
eating disorder had an increased risk of peripartum depression and/or anxiety than the 
referent (OR 2.17, CI 1.4-3.4) and operative delivery (OR 1.96, CI 1.3-3.0) after 
adjusting for confounding factors. WWE and comorbid eating disorder also had 
significantly more preeclampsia (7.9% vs 3.7%, p<0.05) than women without 
epilepsy. When adjusting for confounding factors this was no longer significant. We 
found that WWE had a significantly higher mean BMI than other women (24.7 vs. 
24.0, p<0.001). 
4.2 Paper II 
Our second paper, Overweight in epilepsy as a risk factor for pregnancy and delivery 
complications, showed that WWE had higher weight (69.5 kg vs 68.0 kg, p<0.01) and 
BMI (24.7 vs. 24.0, p<0.001) prepregnancy than other women. WWE were also 
significantly younger (29.2 years vs. 29.8 years, p<0.01) than non-epilepsy women, 
and had more adverse socioeconomic factors (single mother, low educational level 
and low household income) (16.4% vs 9.5 %, p<0.001). WWE were more overweight 
38.4% vs 31.3%, p<0.001) and obese (13.2% vs 9.6%, p<0.01) than women without 
epilepsy. Women using carbamazepine had the highest rate of overweight with 49.4% 
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being overweight, and women using valproate had the highest rate of obesity (20.8%). 
Women using lamotrigine were not significantly different to women without epilepsy 
in terms of overweight or obesity. 
 Compared to normal-weight women without epilepsy, WWE and overweight 
had a significantly increased risk of all adverse pregnancy and delivery 
outcomes tested, except for SGA weight and SGA head circumference. 
 When adjusted for covariates of adverse socioeconomic factors, WWE and 
overweight had a significantly increased risk of caesarean section, excessive 
bleeding during delivery and severe depression and anxiety symptoms 
compared to overweight women without epilepsy.  
 Compared to normalweight WWE, overweight WWE had an increased risk of 
caesarean section, preeclampsia, gestational hypertension and neonatal transfer 
of the child to a pediatric unit. 
 Overweight women using lamotrigine (n=38) had a significantly higher risk of 
caesarean section, severe depression and anxiety peripartum, SGA infants 
(2.5th percentile) and neonatal transfer than overweight women without 
epilepsy.  
 Overweight women using valproate (n=22) had no significant increased risk of 
any adverse outcomes tested compared to overweight women without epilepsy, 
whereas overweight women using carbamazepine (n=41) had an increased risk 
of SGA (10th percentile) compared to overweight women without epilepsy. 
4.3 Paper III 
In our third paper, Young people with epilepsy have an increased risk of eating 
disorder and poor quality diet, we studied individuals between 13 and 19 years of 





compared to the referent (aOR 1.79, CI 1.0-3.0). There was also an increased risk of 
having an unhealthy diet (aOR 1.67, CI 1.3-2.2) and youth with epilepsy were less 
satisfied with their own appearance (aOR 0.69, CI 0.5-0.9). There were no differences 
in mean weight or BMI between groups. Individuals in the epilepsy group were more 
likely to smoke than the reference group (32.9% vs 24.2%, p<0.01). 
There was some gender differences in our study. Females with epilepsy were more 
likely to have a daily consumption of sugar-containing soda, potato chips, candy, or 
French fries than females without epilepsy (aOR 2.16, CI 1.5-3.2). Males with 
epilepsy were more often dieting than males in the reference group (aOR 3.12, CI 1.2-
7.9), and also reported being less satisfied with their looks (aOR 0.44, CI 0.3-0.7). 
Dieting and poor satisfaction with own appearance did not feature as prominently in 
females with epilepsy. In a multivariate model we found an association between 
having an eating disorder and dieting within the epilepsy group (OR 47.9, CI 4.5-
512), as well as an inverse association between satisfaction with own appearance and 
dieting (OR 0.05, CI 0.01-0.2). 
A group consisting of youth with asthma scored between the epilepsy group and the 
referent for all variables tested. 
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5. Discussion 
5.1 Methodological considerations 
5.1.1 Population-based studies 
This study includes observations from two population-based materials. MoBa is a 
prospective cohort study which is linked to MBRN, and the Health Profile for 
Children and Youth in Akershus is a cross-sectional study. Population-based 
questionnaire studies have many strengths and some limitations. Population based 
cohorts or cross sectional studies typically have large numbers of participants that 
increase statistical power. Population-based studies also provide study subjects with a 
wider range of disease severity compared to hospital-based populations. The main 
limitation is the lack of detailed clinical information, for example a precise diagnosis 
of epilepsy and epilepsy severity. With this methodology there is no randomization of 
exposure, and this makes observational studies more vulnerable to systematic errors. 
5.1.2 Bias 
Any comparison of groups in research with the ambition of detecting significant 
differences between these groups, aims at detecting the true difference. Selection bias 
is one important aspect that can skew results away from detection of true differences. 
Recall bias is another such factor.  
Selection bias 
Selection bias includes all are factors that influence or distort study participation. This 
results in a skewed relation of exposure and outcome in those who participate, 
compared to all those who theoretically should have been eligible for the study (124). 
In our case with MoBa, an example would be that people with epilepsy as a group 





health issues than other women. This means that regarding inclusion into a study of 
this scale, with multiple and time consuming questionnaires to complete, a higher 
proportion of educated and intellectually well-functioning women might be included, 
and the inclusion rate of only 41% (119) may reflect this point. Women with severe 
epilepsy, which often includes cognitive impairment, are probably rarely included in 
MoBa. This will skew results in a way that had all WWE been included, also all 
women scoring in the lower brackets on scales for cognitive performance, education 
and mental health, the differences compared to other women in outcome such as 
eating disorders and overweight would expected to be even greater. On the other hand 
a study considering selection bias in MoBa found that the prevalence of epilepsy ≈ 
0,7% is similar to that of the general population in Norway (125). This may reflect 
that inclusion of women with cognitive challenges and/or mental health issues in the 
non-epilepsy group is also rare. 
With an inclusion rate of only 41% there is a wide range of possible selection biases, 
and motivation for study-inclusion may differ among groups. In chapter 1.3.1 stigma 
in epilepsy is considered. WWE will be aware of the stigma attached to a diagnosis of 
epilepsy, and perhaps especially in relation to pregnancy. This can influence their 
willingness to participate, thinking they don’t want to highlight possible flaws and 
preexisting notions about risk assessment in pregnancy in WWE. This may be 
particularly evident in high risk pregnancies, such as women who have frequent 
seizures or use high dosages of AEDs. 
MoBa is a register where only pregnant women are included. Women who are able to 
get pregnant are generally part of the more healthy part of the population. For 
anorexia nervosa, one diagnostic criteria is amenorrhea. Individuals with anorexia 
nervosa has therefore a decreased chance of becoming pregnant. This creates a 
selection bias as very few with symptomatic anorexia nervosa will be included in 
MoBa. To avoid this bias the criterion of amenorrhea for anorexia nervosa was 
excluded in our study. 
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Another selection bias in MoBa was due to the questionnaires only being available in 
Norwegian, excluding some women with background from ethnic minorities. 
In the Health Profile for Children and Youth in Akershus study the study design was 
different in that chosen participants had to fill out questionnaires during school hours. 
This made the participation rate much higher, 85% (126), which probably will make 
selection bias/volunteer bias less pronounced. All children in the chosen schools were 
invited to participate. Also because of the high response rate and the population-based 
nature of the study we were able to avoid overestimation of adverse outcome that is a 
common feature in clinical materials. A total of 0,4% of Norwegian children in 2002 
did not attend general public schools (127). Youth with a very active and severe 
epilepsy, including severe intellectual disability, will not have been included in the 
study as they did not attend ordinary schools. Of eligible participants, 15% did not 
answer the questionnaires. We know little about this group, but we know that people 
with severe epilepsy tend to suffer in terms of school attendance (80). If there is a 
higher frequency of pupils with active epilepsy among non-participants, this will 
serve as a selection bias. Thus, it may be assumed that our findings would be even 
more profound had all adolescents with epilepsy been included.  
Recall bias 
Recall bias appears when case- and control groups have a different recollection of 
events. This may be due to different awareness on a certain topic between 
participants. WWE may previously have been aware of a link between epilepsy and 
eating disorders, and thus be more likely to report symptoms of eating disorders than 
others. Collection of our material was finished in 2008, and such awareness may not 
have been clear at that time. Although our material in MoBa for the most part is 
prospective, some variables will have been retrospective, and in retrospective data 
there is a possibility for inaccuracy in recalled information. Retrospective information 
of weight prepregnancy was used. The questions about eating disorders in MoBa are 





interviews might have yielded more precise diagnostic information both in terms of 
eating disorders, and in terms of the epilepsy diagnosis.  
In the Health Profile for Children and Youth in Akershus study the issue with 
retrospective recollection of events is more prominent. Retrospective dietary 
information is generally hard to remember, and recall accuracy may also be different 
among groups. Young people with eating disorders are more likely to be aware and 
focused on diet, and will be more likely to remember accurately. 
The diagnosis of epilepsy may also be influenced by uncertain recollection or general 
uncertainty about diagnosis. A limitation in both materials used is little clinical 
information about type of epilepsy, diagnostic features and certainty of diagnosis. A 
follow-up study of MoBa has been conducted with the purpose to validate the 
diagnosis of epilepsy (128). All MoBa participants were sent follow-up 
questionnaires regarding complementary information about epilepsy diagnosis and 
AED-use. Hospital records of MoBa participants residing in Western Norway (n=40) 
were examined to further clarify epilepsy diagnosis, and blood samples collected in 
MoBa were examined for AED-detection (128). Half of the 300 women returned the 
questionnaire and 98% of these women confirmed a diagnosis of epilepsy. When 
comparing hospital records for women in Western Norway, the epilepsy diagnosis 
was confirmed in 95% of cases. This validation used the previous definition of 
epilepsy, and not the current definition described in chapter 1.1. Similarly, AED-use 
was detected in 95% of the cases where a mother had reported using AED. In 
conclusion, the reported epilepsy diagnosis in MoBa was in general confirmed by the 
validation studies.   
Channeling bias 
When drugs of similar indications are prescribed to a group of patients with different 
prognostic factors, it is called channeling bias (129). In our MoBa material this will 
be a probable bias, especially in women who use lamotrigine. Lamotrigine is also 
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used as a mood stabilizer and neurologists may have an inclination to prescribe this 
particular drug to women with psychiatric symptoms, and this could be a factor when 
considering the high risk of severe peripartum depression and/or anxiety in 
overweight women using lamotrigine. 
Missing data 
Missing data was a substantial challenge in collecting our data. Information about ED 
was only available for 73.171 pregnancies in MoBa. This means that close to 30% of 
women did not answer one or more questions about ED in the questionnaires. This 
will increase the possibility of bias, especially selection bias, as we do not know the 
characteristics of the women who had missing data. A way to offset missing data is by 
imputation, a statistical method to reduce the effects of missing data. When 
imputating data there is a risk of losing precision. We did not imputate for any data in 
our three papers, because we did not want to lose precision in an outcome variable.  
5.1.3 Confounding 
When investigating the causal effect of variable a to variable b, in example if epilepsy 
by itself causes overweight, it is important to be aware of the possibility of a variable 
c that influences both a and b; a confounder. 
 A confounder is defined the following criteria (130): 
 A confounder must influence the outcome by a different pathway than the 
studied exposure. 
 The confounder cannot be an intermediary in the causal pathway between 
exposure and outcome. 
 The confounder must be associated with the studied exposure. 
For epilepsy and overweight multiple confounders were considered, such as education 





logistic regression model, and as a result minimize the effect of confounding factors. 
We also adjusted for smoking, parity and being a single parent. In the Health Profile 
for Children and Youth in Akershus study, we were able to adjust for smoking and 
perception of family economy, using logistic regression.  
Although multiple confounders were adjusted for, there is a possibility of hidden, 
additional confounders. Hidden confounders are variables that are either not known or 
variables that are unavailable for statistical adjustment, the latter called unmeasured 
confounders. 
Especially in studying youth with epilepsy from Akershu,s we would have preferred 
to have more socioeconomic data to account for. Self-reported perception of family 
economy is a subjective measure of socioeconomic status and may not reflect true 
values. We would have liked to be able to adjust for family structure, parents’ 
educational level and family income, as these are known confounders and valid 
measures of socioeconomic status. 
By adjusting for confounders in statistical models we were able to obtain better 
measure of true group-level differences, and as such increase specificity. Although 
specificity increases, there is a possibility that sensitivity decreases by using this 
method. Methods should be chosen to balance sensitivity and specificity in an optimal 
way. 
It is important to differentiate between mediators and confounders (see the definition 
of a confounder, second criterion). An example in our study is the use of AED. AED 
in some cases increases weight and thus works as an intermediary between the causal 
effect of epilepsy (exposure) and overweight (outcome). We acknowledged this by 
comparing WWE with and without use of AED, “stratification”. We also compared 
the effect of different subgroups of AEDs, but statistical power was a challenge for 
the majority of such subgroups due to small numbers. 
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A challenge we have been aware of in our studies is collinearity. This is when two 
variables are highly correlated and this leads to difficulty in statistically separating 
effects of these variables, meaning effect-estimates will be unstable (124). When 
comparing variables, and when adjusting for specific socioeconomic variables, we 
have tried to avoid this potential pitfall. 
When adjusting for confounders there needs to be an awareness of the possibility of 
overfitting. This is a statistical phenomenon that can occur when the ratio of the 
number of adjusting factors to the number of events is less than 1:10 in a logistic 
regression model (131). Overfitting will lead to inflated effect estimates. In some of 
the comparisons in our work, for example studying overweight women using 
lamotrigine, we cannot exclude the possibility that effects estimates is exaggerated 
due to overfitting. However, we do not find it likely, as the crude estimates was very 
similar to the adjusted estimates. 
5.1.4 External validity 
External validity refers to the generalizability of the study population. To which 
degree can we transfer associations in the study population to the general population? 
MoBa is a population based cohort study. Population based cohort studies covers 
people from all parts of society, and in our case from all over the country. This 
increases the study’s generalizability. A large study population also increases 
generalizability. In cohort studies a specific characteristic is often included to get a 
representative study population (132). In MoBa, only pregnant women were included. 
This makes it difficult to make generalizing conclusions beyond the target population. 
The Health Profile for Children and Youth in Akershus study is a cross sectional 
study with a large number of participants. Its external validity is good due to a very 
high response rate of 85%. This was due to the study design where children and 
adolescents gave their contribution during school hours and in the class-room. 





school system with more than 96% of children attending state funded schools, a 
representative selection was obtained. 
Consistent findings in two different study populations, such as increased risk of eating 
disorders among people with epilepsy both in MoBa and the Health Profile study, also 
increases external validity. 
5.1.5 Errors 
Random errors can occur during inclusion, registration and analysis. Level of 
precision Confidence intervals (CI) mirrors the level of precision of results. A wide 
CI means low precision, and precision increases as CIs narrows. A way to reduce the 
influence of random errors is to increase the study population. In our materials we 
have large study populations, but for analysis of small subgroups there is a possibility 
that random errors influence results. One example is analysis of lamotrigine users 
with overweight in MoBa (n=38), where it is possible that random errors could have 
influenced risk estimates in pregnancy for this group.  
5.2 Discussion of results 
5.2.1 Epilepsy and eating disorders 
In our material from the Health Profile for Children and Youth in Akershus Study, we 
found that youth with epilepsy more often than others were seeking help of health 
personnel for eating disorders. Tegethoff et al studied the temporal associations 
between mental disorders and physical diseases in adolescents (13-18 years) with 
mental-physical comorbidities in a nationally representative United States cohort 
(133). They found a significant association between epilepsy and any eating disorder 
(HR 6.27, CI 1.58-24.96). In that study, diagnoses were self-reported. It is 
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hypothesized that an association between epilepsy and eating disorders arises from a 
right hemispheric focus and right frontal intracerebral lesions because of their close 
relationship to the limbic system (134). This is based on case-reports where eating 
disorders in patients with epilepsy resolved after right temporal lobe lesions (134).  
We found an increased risk of eating disorders also among pregnant WWE. We were 
able to distinguish between the different types of eating disorders due to the questions 
in MoBa covering diagnostic criteria from DSM-IV. The most frequent eating 
disorder among WWE was weight inducing types such as binge eating disorder, but 
also the outcome of impaired bodyimage was significantly increased in the epilepsy 
group. As described in methods this is a variable containing questions mirroring 
diagnostic elements in anorexia nervosa, but criteria of amenorrhea and low BMI was 
left out. The study population will not have low-weight induced amenorrhea as they 
are pregnant women, nor is low BMI compatible with pregnancy. An edited version 
of these criteria was therefore necessary to get an impression of mental health 
challenges in a population of pregnant women. This is in line with previous studies of 
eating disorders in MoBa (111). 
The results of two similar variables in the two different materials, impaired body 
image in MoBa and satisfaction with looks in Health Profile, are coinciding. This 
means that a negative personal image in people with epilepsy debuts early, at least in 
adolescents, and continues later in life. A negative personal image, or bodyimage, is 
the root of developing an eating disorder. We would hypothesize that stigma plays a 
part in the early development of impaired selfworth in people with epilepsy. An 
individual exposed to stigma will feel as an outsider or less normal. Striving to be 
normal, body appearance is easier to control or change than perhaps the epilepsy 
diagnosis is, and therefore youth and adults will be at risk of developing an eating 
disorder. 
Recommendations to screen school aged youth with active epilepsy for difficulties in 
school achievement (80) and for psychiatric comorbidity such as depression and 





resources to children and adolescents in need of extra care. However, it is important 
to locate resources to this task in clinical departments, as time shortage may render 
doctors unable to fulfill the recommendation. Systematically organizing for example 
epilepsy nurses to undertake screening for these disorders, may be a solution. A 
similar approach should be taken in dealing with eating disorders, both in youth, but 
also later in life, as our study reveals that this is a frequent challenge for people with 
epilepsy. 
5.2.2 Epilepsy and overweight 
We found that WWE are more overweight than other women without epilepsy. 
Several AEDs are weight inducing, such as valproate, carbamazepine, and pregabalin 
(92). 
Valproate is weight inducing in patients on such drug treatment for either epilepsy or 
migraine (135-137), ranging from an average 2.0 kg weight increase after one year to 
an increase of 5.8 kg after 32 weeks. Lamotrigine is considered to be weight neutral 
(136, 138). 
We have found that WWE and overweight have an increased risk of pregnancy 
complications, as well as an increased risk of poor outcome for the child. This risk 
was increased compared to normal-weight women without epilepsy, but also 
compared to normal-weight WWE, and compared to overweight women without 
epilepsy. When AEDs are prescribed to fertile WWE weight-gain and overweight 
should always be considered. 
The association between AED use and overweight in our study was modest, and this 
suggests that the observed increase in BMI was mediated by other factors as well. As 
discussed in the previous chapter, the eating disorder with the highest frequency in 
WWE was binge eating. This is a weight inducing eating disorder, and could play a 
part in the increased BMI in the epilepsy group.  
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We found no difference in BMI when comparing adolescents with epilepsy to 
adolescents without epilepsy. However, we found that youth with epilepsy were more 
prone to have an unhealthy diet, meaning daily consumption of candy, sugar-
containing soda, potato chips, or French fries than the controls. It was therefore rather 
surprising that overweight did not occur with an increased frequency in the epilepsy-
group.  
Previous studies have found an association between epilepsy and overweight. One 
study found an association between obesity, idiopathic generalized epilepsy and 
family history of epilepsy in a population recruited from an adult epilepsy clinic 
(139). In another study, the epilepsy group participated less in physical activities and 
had a higher BMI, supporting that overweight in epilepsy at least in some part is 
caused by lifestyle (98). In our material of youth in Akershus, youth with epilepsy 
were found to be as active as the reference group. Neither did the epilepsy group have 
more overweight, thus underlining the theory that these two factors are associated. 
We were not able to study physical activity in MoBa. It is possible that physical 
activity decreases in the epilepsy group when they become adults, when organized 
sport-activities in school are no longer available. Physical activity could therefore be a 
mitigating factor in nullifying other risk factors such as unhealthy diet, use of AED 
and weight inducing eating disorders.  
Previously people with epilepsy have been discouraged to participate in physical 
activities (65), and this recommendation may have lead to less exercise and increased 
rates of overweight in this group. In a Norwegian study of outclinic patients, exercise 
was reported as a possible precipitant of seizures in 10% of cases. The majority of 
patients had no adverse effect of training, and a third reported that physical exercise 
contributed to improved seizure control (65). Exercise should be encouraged for 
people with epilepsy, as well as for the population as a whole. Physical activity has 
during pregnancy been found to have a positive effect on birth outcome as low 





once a week (140), supporting a recommendation of physical activity also in pregnant 
WWE.  
Overweight/obesity is a significant secondary health problem in youth with 
intellectual disability and adolescents with intellectual disability is at a higher risk of 
being overweight/obese than their peers (141). This is also evident in adult 
populations (142). Cognitive impairment is more frequent in patients with epilepsy 
than in a population without epilepsy, and this may be another contributing factor to 
overweight in epilepsy. 
5.2.3 Epilepsy and outcome for pregnancy and delivery 
We have found that overweight is a significant contributing factor for the increased 
risk of pregnancy complications in WWE, as WWE and overweight have more 
complications than both normal weight WWE, and overweight women without 
epilepsy. Epilepsy is a known risk factor for complications during pregnancy and 
delivery, and for child outcome (42, 44, 45, 52, 53, 57, 66). Mechanisms behind these 
findings are scarcely studied, and risk stratification is needed. Overweight is 
important as it is a modifiable factor. 
For some of the variables tested, epilepsy and overweight had additive effects on 
several outcomes, including caesarean section, excessive bleeding during delivery, 
and transfer to a neonatal ward. Caesarean section is increased in most chronic 
diseases (143). In regards to epilepsy there is an indication for caesarean section if 
seizures occur during labor, or the patient is unable to cooperate due to sedation 
(144). In hypertensive disorders, such as preeclampsia, elective caesarean section is a 
frequent mode of delivery (145). In our material, preeclampsia rates were increased in 
women having a caesarean section, and both with and without epilepsy. This could 
therefore have been an indication for caesarean section in both groups. Preeclampsia 
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alone cannot alone explain the full effect overweight had on rates of caesarean section 
in WWE. 
We stratified our material so that we were able to compare WWE using AEDs to 
those who did not. AED use had an effect on risk of excessive bleeding, transfer of 
the child to a neonatal ward, and having small for gestational age children. Vitamin K 
supplements before birth are often given to women using enzyme-inducing AED such 
as carbamazepine and phenytoin to avoid bleeding (45). AED can also cause 
excessive bleeding due to uterine atony (45). In our study an increased risk of 
bleeding during delivery was seen for overweight women using AED compared to 
other overweight women, but not compared to normal weight WWE without AED. 
This implies AED use could be a causative factor for bleeding. 
Overweight women using lamotrigine had increased odds ratios for several 
complications (figure 5). Lamotrigine users with overweight was a relative small 
group, containing just 38 individuals in that study, and thus the statistical power is 
low with wide confidence intervals. Lamotrigine is also used for psychiatric 
diagnoses such as depression and anxiety. This could be a source for channelling bias, 
where physicians are more prone to prescribe lamotrigine to WWE and comorbid 
psychiatric disease. This will increase the proportion of psychiatric challenges in the 
lamotrigine group, and again lead to variables such as caesarean section and neonatal 
transfer being more frequent in this group. However, lamotrigine is often the drug of 








Figure 5: Lamotrigine users with overweight at risk, from (146). 
Overweight in mothers with epilepsy is a risk factor for several obstetrical 
complications. An interesting outcome which we so far have not been able to study is 
overweight in mothers as a risk factor for epilepsy in the offspring. Razaz and 
coworkers recently published a paper where they used two large population based 
registers in Sweden (Sweden Medical Birth Register and National Patient Register). 
More than 1.4 million children were included in the study and 7592 (0.5%) were 
diagnosed with epilepsy. They found that rates of childhood epilepsy increased with 
maternal overweight or obesity in a dose-response manner (147). The authors 
hypothesize that obesity-induced inflammation affects neurodevelopment in the foetus 
and that this could be a mechanism for epilepsy in the child. Another theory is that 
mothers with overweight have a greater risk of pregnancy-associated diseases such as 
hypertensive disorders and diabetes, and that this may contribute to epilepsy in the 
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child. Maternal epilepsy is a risk factor for epilepsy in the child also as a genetic 
heritability (148). It is very interesting that also maternal environmental factors seem 
to have an effect. 
5.3 Conclusions 
Overweight are more frequent in pregnant WWE compared to women without 
epilepsy. The combination of overweight and epilepsy exposes mother and child to a 
significantly increased risk of complications during pregnancy and in the perinatal 
period. Therefore, overweight WWE should be considered as a high-risk group during 
pregnancy and should be monitored closely in terms of mental health, symptoms of 
preeclampsia, diabetes, and intrauterine growth restriction. Referral to a nutritionist 
should be considered for WWE, both when AED treatment is started and when 
planning a pregnancy. 
Eating disorders are frequent in youth with epilepsy, and also in pregnant WWE. This 
is especially valid for weight-inducing eating disorders and underlines the importance 
of intervention with nutritionists and increasing awareness of health issues linked to 
overweight in epilepsy.  
5.4 Importance and outcome of research 
Our findings in this study have been incorporated into the new national guidelines for 
epilepsy treatment and follow-up (149) . Information about the increased risk of 
complications during pregnancy for overweight WWE have been included in an 
information folder produced by the Norwegian Epilepsy Patient Organisation (150). 
Both papers on pregnant women was also cited in a recent authoritative review paper 





5.5 Future directions 
Future research is still needed on this topic. How do the individual antiepileptic drugs 
influence pregnancy and delivery? To what degree to they cause overweight? People 
with epilepsy is a heterogenic group, and how do epilepsy-types differentiate in terms 
of comorbidity? A register with better information about what kind of epilepsy each 
participant have is integral to better stratification and investigation of subgroups. A 
register is also important to ensure the prospective nature of research in the field of 
pregnancy among WWE where women would be included in the register before they 
become pregnant. In Bergen, the recently started project EPI-REG, has set aim to 
fulfil this. Questionnaires in EPI-REG has partially been designed on the back of 
results from research performed in Bergen Epilepsy Research Group (BERG), and 
also due to results presented in this thesis. An emphasize has been put on noting BMI 
and questions have been designed to monitor mental health, included signs of eating 
disorders. 
We are also using EPI-REG to build a large bio-bank including a large set of blood 
samples. We have also approval for inclusion of placenta biopsies from women with 
epilepsy harvested after delivery. This will enable research in genetics in people with 
epilepsy, but perhaps more exciting studies of epigenetics and gene-environment 
interactions in relation to epilepsy and comorbidities. 
Another way of increasing statistical power is to merge registers. This leads to a 
higher number of participants and high statistical power, but also generate better 
opportunities for stratification and investigation of subgroups, in example subgroups 
of people using different antiepileptic drugs. SCAN-AED (www.SCANAED.org) is a 
new initiative from BERG where information on all births in the Nordic countries the 
last 15 years are included to study health consequences of AED exposure during 
pregnancy. Health registers (the birth registers, prescription databases, hospital 
registers and cancer registers) are linked with socioeconomic data from the National 
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Statistical agencies in Norway, Sweden, Denmark, Iceland and Finland. The data are 
linked on the individual level, and the linked files are pooled to one file to enable 
sophisticated regression models. The population encompasses about 4.5 million births 
where more than 20.000 have been exposed to AED.  There are more than 4500 births 
exposed to lamotrigine. As all the medical birth registers in the Nordic countries 
include information on maternal BMI, it will be possible to study the combined risk of 
lamotrigine and overweight on pregnancy outcome in detail.   
Another possibility to increase number of participants is to combine MoBa data with 
data from The Danish National Birth Cohort which is the Danish equivalent to MoBa. 
This is currently just at a planning stage, but could be a focus point for BERG in the 
future. 
There are still a lot of unknown variables and uncertainties in epilepsy. As I have 
pointed out in this thesis there are challenges in everyday treatment and interaction 
with people with epilepsy, and epilepsy is still a huge challenge in terms of future 
research. This should inspire further work in this field to potentially better lives and 
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1. Introduction
Antiepileptic drug (AED) treatment is used by 0.2–0.7% of
pregnant women [1,2]. Several obstetrical complications such as
preeclampsia, gestational hypertension, caesarian delivery, con-
genital malformations and low birth weight occur more frequently
in these women than in women without epilepsy [3]. Adverse birth
outcomes in women with epilepsy (WWE) are believed to be
mediated by AED use, although the exact mechanisms of action
and the role of confounding factors remain unclear. Comorbid
eating disorders (ED) are an unexplored potential contributor to
pregnancy complications in WWE.
Using data from The Norwegian Mother and Child Cohort Study
(MoBa), Reiter et al. [4] found an increased life time prevalence of
self-reported, unspecified ED in pregnant WWE. Rai et al. also
found an increased frequency of ED (OR 2.9) in non-pregnant
persons with epilepsy [5].
Adverse pregnancy outcomes are more frequent in women with
ED, especially for the subgroup with binge eating disorder (BED)
[6]. Women with BED deliver babies that are large for gestational
age and have an increased risk of caesarian section. An increased
rate of miscarriages has been noted in both anorexia nervosa (AN)
Seizure 28 (2015) 81–84
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A B S T R A C T
Purpose: The aim was to investigate the prevalence of eating disorders and its relation to pregnancy and
delivery complications in childbearing women with epilepsy (WWE).
Method: This study is based on The Norwegian Mother and Child Cohort Study (MoBa) linked to the
Medical Birth Registry of Norway. Epilepsy was reported in 706 pregnancies. The remaining cohort
(n = 106,511) served as the reference group. Eating disorders were diagnosed using DSM-IV criteria
adjusted for pregnancy. The risk of preeclampsia, gestational hypertension, diabetes and weight gain
during pregnancy as well as delivery outcome (small for gestational age, large for gestational age,
ponderal index, low APGAR score, small head circumference) were calculated as odds ratios (ORs) with
95% confidence intervals (CIs) adjusted for maternal age, smoking, parity and socioeconomic factors.
Results: Pregnant WWE were significantly more likely to have binge eating disorder (6.5% vs. 4.7%,
p < 0.05). WWE and comorbid eating disorders had significantly more preeclampsia (7.9% vs. 3.7%,
p < 0.05), peripartum depression and/or anxiety (40.4% vs. 17.8%, p < 0.001) and operative delivery
(38.2% vs. 23.5%, p < 0.001) than the reference group without epilepsy or eating disorders. After
adjustment for confounders, a significantly increased risk of operative delivery (OR 1.96, CI 1.26–3.05)
and peripartum depression and/or anxiety (OR 2.17, CI 1.40–3.36) was demonstrated.
Conclusion: Eating disorders in WWE contribute to the increased risk of pregnancy and delivery
complications. Health personnel should be aware of eating disorders in WWE and refer them for
treatment before pregnancy.
 2015 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
* Corresponding author at: Department of Neurology, Haukeland University
Hospital, Jonas Lies vei 65, N-5021 Bergen, Norway. Tel.: +47 95729056;
fax: +47 55975164.
E-mail addresses: kolstadeivind@gmail.com, evid@helse-bergen.no (E. Kolstad).
Contents lists available at ScienceDirect
Seizure
jou r nal h o mep age: w ww.els evier . co m/lo c ate /ys eiz
http://dx.doi.org/10.1016/j.seizure.2015.02.014
1059-1311/ 2015 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
and bulimia nervosa (BN) [7,8]. ED have also been linked to an
increased risk of stillbirth, low birth weight, low Apgar scores,
breech presentation, lower weight-for-length offspring trajecto-
ries and cleft lip and palate [9,6,10].
As both epilepsy and ED increase the risk of complications
during pregnancy and delivery, we investigated the prevalence and
subtypes of this combination during pregnancy, and estimated
possible impacts of ED in epilepsy on pregnancy and birth outcome
in WWE.
2. Materials and methods
The Norwegian Mother and Child Cohort Study (MoBa) is a
prospective population-based pregnancy cohort study con-
ducted by the Norwegian Institute of Public Health. Participants
were recruited from all over Norway from 1999 to 2008. The
women consented to participation in 40.6% of the pregnancies.
The cohort now includes 114,500 children, 95,200 mothers and
75,200 fathers. The response rate was 45% [11]. The women
received standardized questionnaires addressing information
on maternal epilepsy, psychiatric symptoms and socioeconomic
status. The MoBa database is linked to the Medical Birth Registry
of Norway that contains information on pregnancy and delivery
complications.
The MoBa database comprises 706 pregnancies in women with
epilepsy and 106,508 pregnancies in women without epilepsy.
Information concerning ED was available for 73,171 pregnancies.
The MoBa epilepsy cohort has been validated [12,13].
The women answered questions in accordance with DSM-IV
criteria for AN, BN and BED. The questions were slightly adjusted
due to the cohort being pregnant, amenorrhea was not required in
AN. We also evaluated ‘‘impaired bodyimage’’ defined as fulfilling
the AN criteria, except for amenorrhea and low BMI criteria. The
frequency of fasting, use of laxantia and vomiting during
pregnancy was investigated. The rates of ED in the women
without epilepsy in the MoBa study have been validated [14].
We investigated the relationship between epilepsy and any
type of ED (except for impaired body image) and hypertension
during pregnancy, diabetes during pregnancy, preeclampsia,
peripartum depression and/or anxiety [15], excessive pregnancy
weight gain (>16 kg), operative deliveries (caesarian section, use
of vacuum or forceps), small for gestational age (<10th percentile),
large for gestational age (>10th percentile), small head circumfer-
ence (<10th percentile) [16], low Apgar score (<7 after 5 min) and
ponderal index (weight/length3, <10th percentile and >90th
percentile). Neonatologists have preferentially used the ponderal
index rather than small for gestational age as an indicator of
nutritional status in the child, and the variable is a predictor of
neonatal disease [17].
IBM SPSS Statistics version 21 was used. We investigated group
differences using Student’s t test and Pearson’s x2 test (Fisher’s
exact test if any cross table cell had an expected count < 5). Binary
logistic regression was used to estimate the odds ratio (OR) with
95% confidence interval (CI) for pregnancy and delivery complica-
tions adjusted for the confounding factors maternal age, parity,
smoking and socioeconomic factors (low household income, low
education or being a single mother).
The study was approved by the Regional Ethical Committee in
Western Norway.
3. Results
WWE in the MoBa cohort more frequently had lower
educational attainment, low income, single parenting, and were
younger than women without epilepsy [15]. They also had
significantly higher weight and BMI than the reference group
(Table 1).
There was a significantly increased rate of BED and ‘‘impaired
body image’’ during pregnancy in WWE compared to women
without epilepsy (Table 1). ‘‘Impaired body image’’ was signifi-
cantly increased in both women using AED monotherapy (6.9%,
p < 0.05, n = 266) and polytherapy (9.4%, p < 0.05, n = 72), as
compared with the reference group (3.6%). No difference in
prevalence was found for bulimia or anorexia before or during
pregnancy.
WWE and comorbid ED had significantly more often pre-
eclampsia (7.9% vs. 3.7%), peripartum depression and/or anxiety
(40.4% vs. 17.8%) and operative delivery (38.2% vs. 23.5%) than
women without epilepsy and no ED (Fig. 1). WWE and comorbid
ED had more peripartum depression and/or anxiety than WWE
without ED (40.4% vs. 24.2%, p < 0.01). No confounding factors
were considered in this analysis.
After adjusting for confounding factors, WWE and comorbid ED
had a significantly greater risk of peripartum depression and/or
anxiety (OR = 2.17, CI 1.4–3.4, p < 0.001) and operative delivery
(OR = 1.96, CI 1.3–3.0, p < 0.01, Fig. 2). After additional adjustment
for AED use, the risk of operative delivery was no longer
significantly higher (OR 1.35, CI 0.7–2.5, p < 0.35).
Table 1









Weight (SD) 68.0 (12.9) 69.5 (13.7)** 69.2 (13.0)* 69.7 (14.3)*
BMI (SD) 24.0 (4.3) 24.7 (4.6)*** 24.6 (4.5) 24.8 (4.8)
Impaired bodyimagee 2356 (3.6%) 30 (6.1%)** 13 (4.9%) 17 (7.5%)**
BEDa pre-pregnancyc 3165 (3.3%) 30 (4.5%) 13 (3.7%) 17 (5.3%)*
BED during pregnancyd 4298 (4.7%) 41 (6.5%)* 21 (6.3%) 20 (6.6%)
Bulimia pre-pregnancyc 1747 (1.7%) 7 (1.0%) 4 (1.1%) 3 (0.9%)
Bulimia during pregnancyd 466 (0.5%) 1 (0.1%) 1 (0.3%) 0 (0%)
Use of laxantia during pregnancyd,f 79 (0.1%) 0 0 0
Fasting during pregnancyd,f 60 (0.1%) 2 (0.3%)* 1 (0.3%) 1 (0.3%)
Vomiting during pregnancyd,f 392 (0.4%) 4 (0.7%) 2 (0.7%) 2 (0.6%)
a BED = binge eating disorder.
b AED = antiepileptic drugs.
c Pre-pregnancy = last 6 months before pregnancy.
d During pregnancy = gestation week 17–19.
e Impaired bodyimage = DSM-IV criteria for anorexia nervosa, but amenorrhea and BMI < 18.5 were not required.
f Use of laxantia, fasting or vomiting at least once a week with the purpose of controlling body weight.
*p < 0.05; **p < 0.01; ***p < 0.001 vs. the reference group.
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4. Discussion
Pregnant WWE have an increased risk of binge eating disorder.
WWE and comorbid ED more often had operative deliveries and
pregnancy related depression and/or anxiety.
In contrast with other psychiatric disorders, ED has rarely been
studied in epilepsy. Using DSM-IV criteria we found slightly higher
rates of ED than reported in non-pregnant patients with epilepsy (5%
point prevalence) [5]. Possibly, earlier estimates of ED in epilepsy did
not include BED. In women without epilepsy, BED is the most
common type of ED during pregnancy [18]. As reproductive health is
negatively affected by ED [19], a lower rate of ED in pregnant than in
non-pregnant WWE is expected. This is supported by Reiter et al.
who found an increased life-time prevalence of unspecified self-
reported ED in pregnant WWE compared with other women in the
same study sample (4.8% vs. 2.9%), but very few reported having such
disorders during pregnancy (0.4% vs. 0.3%). Similarly, unspecified ED
has been found in only 0.8% of women without epilepsy after
delivery [20].
The subgroup of WWE with ED had a numerically higher risk
than the rest of the epilepsy cohort for the majority of pregnancy
and delivery complications investigated. However, the power to
find an ED related difference surpassed 60% only for peripartum
depression and/or anxiety as well as operative deliveries. Our
results were probably driven by BED. This disorder increases the
risk for complications during pregnancy and delivery, and adverse
birth outcome, such as higher birth weight babies, higher risk of
large for gestational age and caesarian section than the referent [6].
There are several explanations as to why WWE with ED have
more pregnancy complications. Women with ED are more likely to
smoke during pregnancy [18]; this is why we adjusted for this in
our binary logistic regression model. Comorbid anxiety, depression
and excessive weight gain may be associated with adverse effects
on pregnancies and birth outcome [21,22]. Furthermore, the use of
AEDs is a risk factor for pregnancy complications [3,12], and partly
Fig. 1. Pregnancy and delivery complications (plot A) and birth outcome (plot B) according to a diagnosis of epilepsy and/or eating disorders. Significance levels are marked
with *, compared with the reference group without eating disorder. W = with, wo = without.
Fig. 2. Complications during pregnancy, delivery and birth outcome. WWE and ED (grey markers) and WWE and no ED (black markers) compared with the reference group (all
other women in MoBa). Risk of complications during pregnancy (plot A) and risk of adverse birth outcome (plot B). The estimates are adjusted for parity, maternal age,
smoking and socioeconomic factors. Depression/anx = peripartum depression and/or anxiety. Op. delivery = caesarian section, use of vacuum or forceps. PI = ponderal index.
SGA/LGA = small/large for gestational age. SGA head = small for gestational age head circumference. Low Apgar: <7 after 5 min.
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mediated the risk for operative deliveries in WWE and ED in
our data.
The prospective design of the MoBa study minimized reporting
bias. The participation rate of 40.6% at first assessment is expected
for population-based studies [23]. A study investigating selection
bias found that epilepsy prevalence was similar in the MoBa study
and in the general Norwegian population [24].
5. Conclusion
The increased risk for complications in WWE with ED during
pregnancy with possible adverse health effects for both mother
and child should be considered and minimized in consultations
both before and during pregnancy.
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Objective: To investigate whether prepregnancy overweight in women with epilepsy
increases their risk for complications during pregnancy and delivery.
Methods: This study is based on The Norwegian Mother and Child Cohort Study
(MoBa) linked to the Medical Birth Registry of Norway. A diagnosis of epilepsy was
reported in 706 pregnancies. Overweight was defined as body mass index ≥ 25
prepregnancy. Overweight women with epilepsy (n = 259) were compared to normal-
weight women with epilepsy (n = 416), and to women without epilepsy with and with-
out overweight (n = 30,516 and n = 67,977, respectively). The risks of pregnancy and
delivery complications were calculated as odds ratios (ORs) with 95% confidence inter-
vals (CIs) adjusted for adverse socioeconomic factors, age, parity, and smoking.
Results: Women with epilepsy were more often overweight than women without epi-
lepsy (38.4% vs. 31.3%, p < 0.001). The majority of pregnancy and delivery complica-
tions were more frequent in overweight women with epilepsy. Compared to
overweight women without epilepsy, the risk was increased for cesarean section (OR
1.6, CI 1.2–2.2, p < 0.001), excessive bleeding (OR 1.4, CI 1.0–1.8, p = 0.04), peripar-
tum anxiety and depressive symptoms (OR 1.9, CI 1.3–2.8, p < 0.001), small for gesta-
tional age children (OR 2.4, CI 1.2–4.8, p = 0.02), and transfer of the infant to a
neonatal ward (OR 1.5, CI 1.1–2.2, p = 0.02). Compared to normal-weight womenwith
epilepsy, the risk of cesarean section (OR 1.6, CI 1.1–2.3, p < 0.05), gestational hyper-
tension (OR 2.0, CI 1.1–3.5, p < 0.05), preeclampsia (OR 2.3, CI 1.2–4.5, p < 0.05), and
transfer of the infant to a neonatal ward (OR 2.2, CI 1.3–3.6, p < 0.01) was increased.
Significance: Prepregnancy overweight in combination with epilepsy entails a strong
negative effect on risk of complications during pregnancy and delivery. In women with
epilepsy and overweight referral to a nutritionist should be considered when an
antiepileptic drug is started as well as when pregnancy is planned. Thesewomen should
be regarded as a high-risk group.
KEYWORDS: TheNorwegianMother andChild Cohort Study, Epilepsy, Overweight,
Obesity, Pregnancy.
Women with epilepsy are a vulnerable group, especially
during pregnancy. Obstetric complications such as depres-
sion, anxiety, preeclampsia, gestational hypertension,
cesarean delivery, congenital malformations, and low birth
weight are reported more frequently than in women without
epilepsy.1–3 Most studies have not been adjusted for over-
weight, even though overweight and obesity are known
causes of complications during pregnancy and delivery, as
well as of adverse birth outcome. Conditions such as
preeclampsia, diabetes during pregnancy, fetal macrosomia,
stillbirth, perinatal death, and postterm pregnancy are all
known to be more frequent in overweight and/or obese
women.4,5 Obese women are more likely to experience ante-
natal and postpartum depression symptoms, with a
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moderate increased risk also for overweight women.6
Antiepileptic drugs (AEDs) are known to influence body
weight.7 AEDs associated with weight gain are gabapentin,
pregabalin, valproate, vigabatrin, and possibly carba-
mazepine. AEDs associated with weight loss are felbamate,
topiramate, and zonisamide. Lamotrigine, levetiracetam,
and phenytoin are believed to be weight neutral.7 It is
unknown whether AEDs have any additional effects on
weight control in pregnancy.
Our first aim was to establish the frequency of overweight
and obesity in women with epilepsy. The effect of over-
weight on complication risk during pregnancy and delivery
has not been investigated in women with epilepsy. Our sec-
ond aim was to compare overweight women with epilepsy
to overweight women without epilepsy, as well as to nor-
mal-weight women with and without epilepsy, to determine
to what degree overweight contributes to the increased com-
plication rate in epilepsy. Because both overweight and epi-
lepsy represent known risk factors for pregnancy and
delivery complications, we wanted to explore the combined
effect of these two factors to see if they had an additive or
potentiating effect on the outcome.
Materials and Methods
The Norwegian Mother and Child Cohort Study (MoBa)
is a prospective population-based pregnancy cohort study
conducted by the Norwegian Institute of Public Health.8,9
Participants were recruited from all over Norway from 1999
to 2008. The women consented to participation in 41% of
all invited pregnancies. The current study includes 107,516
pregnancies, where epilepsy was reported in 713 cases.
Women answered the following question in week 17–19 of
pregnancy when they were included in the study: Do you
have or have you had epilepsy? They were also instructed to
provide information about any medication taken in conjunc-
tion with the illness. Diagnosis of epilepsy and AED use in
MoBa has been validated with further retrospective ques-
tionnaires, by AED plasma measurements as well as investi-
gation of hospital records on patients from Western
Norway.10 The dataset was also linked to the Medical Birth
Registry of Norway (MBRN), a national health registry con-
taining information on all births in Norway during the study
period. The attending physician or midwife collects medical
information during delivery for all births after 12 weeks of
gestation, including information on epilepsy and AED
intake. The retrospective questionnaires confirmed the epi-
lepsy diagnosis in all but seven women. The examination of
patient journals confirmed the epilepsy diagnosis in 95%
when applying the International League Against Epilepsy
(ILAE) criteria.11,12 With the help of blood samples from
the MoBa Biobank, the detection rate of AEDs in blood of
women who reported taking such drugs was 95%. This leads
to a positive predictive value (PPV) of 98.8% and a speci-
ficity of 99.9%.
The attrition rate was low. In women without epilepsy,
647 (0.6%) died pre-birth and 102 children (0.1%) died peri-
natally. In the epilepsy group, 8 children (1.2%) died pre-
birth and 2 (0.3%) children perinatally. There were no sig-
nificant differences between groups in terms of stillborns
(p = 0.1) or perinatal deaths (p = 0.1).
The women reported prepregnancy weight and height.
MBRN also contains prepregnancy and weight at the end of
pregnancy. We calculated the body mass index (BMI) in
MoBa according to BMI = kg/m2 Overweight was defined
as BMI ≥ 25 and obesity as BMI > 30. In gestational week
30 and 6 months postpartum, the women completed the
Hopkins symptom checklist, an eight-item version of a vali-
dated screening tool designed to detect depression and anxi-
ety in population studies.13 Severe anxiety and depression
were defined as a mean score > 2.0 in both the depression
and anxiety domains.3 Information concerning pregnancy
and obstetric complications such as cesarean section, exces-
sive bleeding during delivery (>500 ml), preeclampsia
(blood pressure > 140/90 mm Hg and proteinuria), diabetes
during pregnancy, gestational hypertension (blood pres-
sure > 140/90 mm Hg without proteinuria), small/large for
gestational age (SGA/LGA) infants,14 head circumference,
transfer of the baby to a neonatal ward, and Apgar score at
5 min after delivery was collected from the MBRN.
When studying complications during pregnancy and
delivery and adverse outcome for the infant, results were
stratified into the following groups: (1) overweight women
with epilepsy (n = 259); (2) overweight women without
epilepsy (n = 30,728); (3) normal-weight women with epi-
lepsy (n = 447); (4) normal-weight women without epi-
lepsy (n = 67,977); and (5) overweight women using
lamotrigine (n = 38), carbamazepine (n = 41), or valproate
(n = 22) in all combinations of drugs. Other specific AEDs
were in numbers too small to allow meaningful analysis.
IBM SPSS Statistics version 21 was used. We investi-
gated group differences using Student’s t-test and Pearson’s
chi-square test (Fisher’s exact test if any cross-table cell had
an expected count < 5). Binary logistic regression was used
to estimate the odds ratio (OR) with 95% confidence
Key Points
• Women with epilepsy are often overweight
• Overweight and epilepsy represent additive risks for
cesarean section, bleeding complications, and neona-
tal transfer
• Overweight women with epilepsy should be regarded
as a high-risk group during pregnancy and be followed
closely
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interval (CI) for pregnancy and delivery complications
adjusted for maternal age, parity, smoking, and socioeco-
nomic factors (low household income, low education,
and/or being a single mother). In this model of logistic
regression, we compared groups 1 and 2, groups 1 and 3,
groups 1 and 4, as well as groups 5 and 2. Additive effect
was defined as epilepsy and overweight, having an inde-
pendent and cumulative effect on risk estimates. We cal-
culated this by comparing groups 1 and 2 and groups 1
and 3. If both comparisons were significant, we regarded
the effect as an additive risk. Potentiating effect was
defined as an increased effect compared to the expected
cumulative risk of two factors. A potentiating (synergis-
tic) effect was investigated by inserting an interaction
term: multiplying epilepsy 9 overweight. If the interac-
tion terms were significant in the logistic regression
model, we regarded the effect as potentiating.
MoBa has obtained a license from the Norwegian Data
Inspectorate. The current study is based on version VII of
the quality-assured data files released for research on epi-
lepsy. The current study was approved by The Regional
Committee for Medical Research Ethics.
Results
Compared to women without epilepsy, women with
epilepsy had a significantly lower age, higher weight,
and BMI prepregnancy, as well as significantly more
adverse socioeconomic factors (Table 1). Women with
epilepsy and overweight had less weight gain during
pregnancy than the nonepilepsy group without over-
weight.
Women with epilepsy were more often overweight and
obese before pregnancy (Fig. 1). We found overweight
in 38.4% of women with epilepsy and obesity in 13.2%
compared to, respectively, 31.3% and 9.6% of women
without epilepsy (p = 0.001 and p = 0.01). There was no
significant prepregnancy weight difference between
women with and without AED use during pregnancy in
the epilepsy group, and there was not any significant dif-
ference between patients using AED in monotherapy and
polytherapy (38.9% vs. 35.3%, p = 0.5). Women using
carbamazepine and valproate had the highest proportion
of overweight and obesity, respectively. For carba-
mazepine users compared to the nonepilepsy group, the
significance levels were p = 0.001 (overweight) and
p = 0.1 (obesity), for valproate users they were p = 0.1
and p = 0.006, respectively. There was no weight differ-
ence for women using lamotrigine compared to the none-
pilepsy group (p = 0.6 for overweight and p = 0.3 for
obesity).
Women with epilepsy and overweight had a high and
significantly increased risk of all adverse pregnancy and
delivery outcomes tested compared to normal-weight




























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Overweight in Epilepsy during Pregnancy
SGA head circumference below the 10th percentile (Fig. 2).
Unadjusted analysis showed that women with epilepsy
and overweight more often had cesarean section,
preeclampsia, hypertension during pregnancy, diabetes dur-
ing pregnancy, small head circumference, and neonatal
transfers compared to normal-weight women with epilepsy
(Table 2, Fig. 2). Compared to overweight women without
epilepsy, women with epilepsy and overweight more often
had cesarean section, excessive bleeding during delivery,
severe symptoms of depression and anxiety, SGA children,
and neonatal transfer of the infant to a pediatric ward
(Table 2, Fig. 2).
When we adjusted for several covariates including
adverse socioeconomic factors, women with epilepsy and
overweight still had significantly higher odds of cesarean
section, excessive bleeding during delivery, and a twofold
increased risk of severe depression and anxiety symptoms
than overweight women without epilepsy (Fig. 3A). When
stratifying the epilepsy group according to AED use,
women using AEDs had an increased risk of cesarian sec-
tion (adjusted [aOR] 1.81, 95% CI 1.2–2.7), excessive
bleeding (aOR 1.56, 95% CI 1.0–2.4), SGA 2.5th percentile
(aOR 3.31, 95% CI 1.3–8.2), and neonatal transfer (aOR
1.69, 95% CI 1.0–2.8) compared to overweight women
without epilepsy (Appendix S1). The epilepsy group with-
out use of AED had an increased risk of cesarian section
(aOR 1.49, 95% CI 1.0–2.2) and severe depression and anxi-
ety (aOR 2.25, 95% CI 1.4–3.7) compared to overweight
women without epilepsy (Appendix S1). Compared to
women with epilepsy and normal-weight, women with epi-
lepsy and overweight had significantly higher adjusted odds
of cesarean section, preeclampsia, gestational hypertension,
and neonatal transfer of the child to a pediatric unit
(Fig. 3B). Of the women with epilepsy and overweight who
had a cesarean section, 12.7% (n = 71) also had preeclamp-
sia, whereas this comorbidity was shared with only 7.4%
(n = 81) of normal-weight women with epilepsy with a
cesarean section delivery (p = 0.28). Similarly, preeclamp-
sia was more frequent in overweight than normal-weight
women without epilepsy having a cesarean section (12.3%
vs. 7.2%, p = 0.001).
Adjusted for confounders, overweight women using lam-
otrigine (n = 38) had a higher risk of cesarean section (OR
3.5, 95% CI 1.8–6.7, p = 0.001), severe depression and anx-
iety symptoms peripartum (OR 2.5, 95% CI 1.0–6.2,
p = 0.04), SGA age infants (2.5th percentile) (OR 4.5, 95%
CI 1.1–19.1, p = 0.04), and neonatal transfers (OR 2.8, 95%
CI 1.3–6.0, p = 0.008) than overweight women without epi-
lepsy (Fig. 4). Normal-weight women using lamotrigine, had
a significant higher risk of cesarean section (OR 2.7, 95% CI
1.7–4.3, p = 0.0001) and excessive bleeding during delivery
(OR 2.3, 95% CI 1.4–3.6, p = 0.0001) compared to normal-
weight women without epilepsy. When comparing over-
weight women using valproate to overweight women without
epilepsy there were no significant increase in any of the
adverse outcomes tested (Appendix S1). Overweight women
using carbamazepine had an increased risk of SGA 10th per-
centile (OR 3.5, 95% CI 1.5–8.3, p = 0.005) compared to
overweight womenwithout epilepsy (Appendix S1).
The reasons for neonatal transfer to a pediatric ward were
similar for all groups examined (Appendix S1).
Figure 1.
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Discussion
Epilepsy is known to cause complications during preg-
nancy. However, there have been no previous studies where
mechanisms behind the increased risk have been targeted.
To improve the pregnancy outcome in women with epi-
lepsy, risk stratification is needed. Our study shows that
overweight contributes significantly to the increased com-
plication risk during pregnancy and after delivery in women
with epilepsy. Both compared to overweight women with-
out epilepsy and normal-weight women with epilepsy, over-
weight women with epilepsy are at an especially increased
risk for several complications during pregnancy and in the
perinatal period. This shows that a significant proportion of
pregnancy-related complications that women with epilepsy
experience is applicable to overweight. This new informa-
tion is important, as overweight is a modifiable risk factor.
We also found that women with epilepsy were more often
overweight than women without epilepsy.
Epilepsy and overweight had an additive effect on out-
come for some of the parameters, including cesarean sec-
tion, excessive bleeding during delivery and transfer to a
neonatal ward. The three most common indications for
cesarean section are failure to progress during labor, abnor-
mal fetal status, and fetal malrepresentation.15 Epilepsy is
an indication for cesarean delivery if a seizure occurs during
the second stage of labor, or the patient is unable to cooper-
ate due to sedation.16 Most chronic diseases increase cesar-
ean delivery rates.17 Elective cesarean section is the most
frequent mode of delivery for women with preeclampsia.18
In women with epilepsy who had a cesarean section,
preeclampsia rates were numerically higher in the over-
weight group compared to the normal-weight group, as also
seen in women without epilepsy. Preeclampsia was there-
fore a reason for operational delivery in both women with
and without epilepsy, but cannot fully explain the additive
effect overweight had on risk of cesarian section in the epi-
lepsy group.
Maternal overweight and obesity in otherwise healthy
women are associated with several adverse outcomes such
as gestational diabetes,19 gestational hypertension,19
preeclampsia,19 cesarean delivery,20 low Apgar score,21
preterm birth,22 stillbirth,23 neonatal death,24 and large for
gestational age (LGA) infant.25 The risk increases with
increasing degrees of overweight/obesity.26 It is not fully
understood whether overweight is a cause of adverse preg-
nancy outcome or whether the association between over-
weight and complications during pregnancy is due to shared
characteristics of both entities, such as adverse socioeco-
nomic factors or poor health. However, we adjusted for
socioeconomic factors (low household income, low educa-
tion, and/or being a single mother) in our analyses, as well
as for smoking, parity, and maternal age. Complications
during pregnancy in overweight women are often attributed
to the increase in gestational diabetes, but overweight
women who are glucose tolerant are still at a greater risk of
adverse pregnancy outcome.27 Therefore, other mecha-
nisms play a part.
Table 2. Complications during pregnancy, delivery, and for birth outcome






















Cesarean section 81 (19.5) 8,420 (12.4) 71 (27.4)**,#,††† 5,769 (18.8) 16 (42.1)*** 10 (24.4) 6 (27.3)
Excessive bleeding 72 (17.3) 9,849 (14.6) 60 (23.2)*,† 5,542 (18.1) 9 (23.7) 9 (22.0) 6 (27.3)
Preeclampsia 16 (3.8) 1,829 (2.7) 21 (8.1)# 1,858 (6.1) 3 (7.9) 4 (9.8) 3 (13.6)
Hypertension during
pregnancy
26 (6.3) 2,905 (4.3) 29 (11.4)# 2,835 (9.3) 6 (15.8) 6 (15.0) 3 (13.6)
Diabetes 1 (0.2) 350 (0.5) 6 (2.4) 636 (2.1) 3 (8.1)* 0 0
Severe depression/anxiety 45 (10.9) 4,067 (6.1) 34 (13.2)***,††† 2,095 (6.9) 6 (15.8)* 4 (9.8) 1 (4.5)
SGA 10th percentile 42 (10.1) 5,147 (7.6) 20 (7.7) 1,623 (5.3) 3 (7.9) 6 (14.6)** 1 (4.5)
SGA 2.5th percentile 9 (2.2) 1,091 (1.6) 8 (3.1)*,†† 378 (1.2) 2 (5.3)* 2 (4.9)* 0
LGA 10th percentile 41 (10.0) 5,940 (8.9) 38 (15.1) 5,107 (16.9) 6 (16.2) 2 (5.0)* 3 (13.6)
SGA head circ 10th perc 43 (10.5) 5,737 (8.6) 15 (6.0)# 1,722 (5.7) 1 (2.7) 5 (12.5) 0
Apgar < 7 after 5 min 9 (2.2) 885 (1.3) 8 (3.3) 558 (1.9) 1 (2.7) 0 1 (4.8)
Neonatal transfer 31 (7.8) 4,726 (7.4) 37 (15.6)*,##,†† 2,996 (10.4) 9 (23.7)** 5 (13.9) 4 (19.0)
Cesarean delivery: either elective or urgent operational delivery; excessive bleeding: >500 ml during delivery; preeclampsia: blood pressure > 140/90 mm Hg
and proteinuria; diabetes during pregnancy: gestational diabetes and diabetes type 2; hypertension during pregnancy: blood pressure > 140/90 mm Hg without
proteinuria; SGA 10th/2.5 percentile or LGA 10th percentile: small/large for gestational age (SGA) babies; SGA head circ 10th perc: small head circumference for
gestational age, 10th percentile; neonatal transfer: transfer to neonatal ward after birth; Apgar score < 7 after 5 min: low score of appearance, pulse, grimace,
activity, and Respiration.
Unadjusted comparisons.
*p < 0.05, **p < 0.01, ***p < 0.001, compared to nonepilepsy with overweight.
#p < 0.05, ##p < 0.01, ###p < 0.001, compared to epilepsy without overweight.
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In our study, overweight contributed more than a
diagnosis of epilepsy to the increased risk of gestational
diabetes, gestational hypertension, preeclampsia, and
delivery of a LGA infant. This effect was not mediated
by AED use, as we also investigated the epilepsy group
by stratifying into groups with and without use of
AEDs. AEDs did have an effect on the risk of excessive
bleeding, having SGA children and transfer of the infant
to a neonatal ward. However, having epilepsy was the
main generator of anxiety and depressive symptoms, as
the risk was increased in women both using and not
using AEDs compared to the other women. Peripartum
depression is frequent in women with epilepsy,28 but
seldom medically treated.29 According to prior investiga-
tions of the MoBa epilepsy cohort, peripartum anxiety
and depression were strongly associated with frequent
epileptic seizures during pregnancy, prepregnancy
depression and anxiety, a history of physical or sexual
abuse, having lost a child, as well as unplanned preg-
nancy. These associations are probably more related to
the epilepsy disorder itself rather than any comorbid
overweight. In addition, the increased frequency of
neonatal transfers to a children’s ward depended more
on having epilepsy than on being overweight, indicating
a greater need for closer observation and/or treatment of
the newborn in maternal epilepsy regardless of maternal
weight.
Because overweight influenced the frequency of preg-
nancy and delivery complications, obese women with epi-
lepsy should be regarded as a high-risk group and receive
extra care in the pregnancy and perinatal period. Blood
sugar levels, blood pressure, and signs of preeclampsia
should be monitored carefully. Additional ultrasound inves-
tigations should be considered in order to detect potential
fetal growth anomalies or malformations. Screening for
maternal symptoms of anxiety and depression is also war-
ranted. Anxiety and depression may cause severe adverse
consequences for the mother and child, and therefore swift
treatment is important.29 Antenatal vitamin K supplements
are often given routinely to women using an enzyme-indu-
cing AED, such as carbamazepine or phenytoin to avoid
bleeding.30 Because the risk of bleeding was increased in
overweight women using AEDs compared to other over-
weight women, but not compared to normal weight women
with epilepsy, AEDs may be the causative factor. AEDs
may also cause bleeding by uterine atony.30
Most previous studies on pregnancy and delivery compli-
cations in epilepsy have not adjusted for overweight and
obesity.2 Such adjustment should be a prerequisite, as we
show that women with epilepsy are more overweight than
control women also in relation to pregnancy. The associa-
tion between weight and AED use was modest, suggesting
that the increased weight also was moderated by other fac-
tors. Weight tends to increase with number of pregnancies,
but there was no difference in parity in women with epilepsy
Figure 3.
(A,B) Risk of complications during pregnancy and delivery.
Epilepsia ILAE
Figure 4.
Risk of complications during pregnancy and delivery for over-
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compared to the nonepilepsy group. Our results are in line
with other reports on weight in epilepsy populations.31–33 In
a study of people with epilepsy recruited from an adult epi-
lepsy clinic; BMI, waist circumference, and information
regarding physical activity were obtained.31 There was an
association between obesity, idiopathic generalized epi-
lepsy, and family history of epilepsy. The epilepsy group
participated less in physical activities and had a higher BMI,
supporting that greater weight in epilepsy is affected by life-
style.32 People with epilepsy have previously been discour-
aged from participation in physical activity because of fear
of inducing seizures.34 The recommendation may have
caused people with epilepsy to exercise less, thereby
increasing obesity rates. Exercise was a seizure precipitant
in 10% of patients with epilepsy.34 However, in the majority
of patients, physical exercise has no adverse effects. One
third of patients claimed that exercise even contributes to
improved seizure control.34 Physical activity during preg-
nancy will also have positive effects on birth outcome. For
women with a BMI < 30, the lowest perinatal mortality was
seen in those performing recreational physical activity at
least once a week.5 Exercise should be encouraged also in
women with epilepsy, and especially during their childbear-
ing years.
In our material, valproate and carbamazepine were partic-
ularly associated with overweight and obesity. AEDs influ-
ence body weight, and some cause overweight.7 A possible
explanation is the effect on hormonal balance. Liver
enzyme–inducing AEDs, as well as valproate, alter levels of
sex hormones and thyroid function,35 which in turn may
affect weight gain. Low serum leptin level is associated with
weight loss in overweight female patients with epilepsy.36
Zonisamide reduces serum leptin levels, and this may
explain the association of zonisamide with weight loss.36
Other AEDs could also influence leptin and associated hor-
mones. There are also indications that epilepsy itself has an
effect on hormonal balance, especially sex hormones,37
which in turn is associated with polycystic ovary syndrome.
This syndrome alters distribution of adipose tissue and
causes overweight. Adipose tissue itself is also an active
endocrine organ that could enhance the effects of AEDs on
hormonal balance.
We found that women using lamotrigine were especially
at risk for complications such as cesarean section and severe
peripartum depression and anxiety if they were overweight.
Giving birth to a very small infant and neonatal transfer of
the child was frequent. The adverse effects on the child did
not seem to apply for women using lamotrigine if they were
normal weight. The increased complication rates were not
seen for overweight women using carbamazepine or val-
proate (Appendix S1). Lamotrigine is considered to be a rel-
atively safe drug during pregnancy,38 although it has been
linked to a greater risk of preeclampsia and bleeding.1
Lamotrigine is associated with reduced seizure control dur-
ing pregnancy, possibly due to increased hepatic drug
elimination during pregnancy.39 This may in part explain
the high complications rates for lamotrigine in our study.
There is also the possibility of selection bias, in that clini-
cians may have subscribed lamotrigine to patients who were
vulnerable in terms of mental health issues such as depres-
sion and anxiety. This is backed up by the increased risk that
overweight women using lamotrigine have of depression
and anxiety peripartum compared to overweight women
without epilepsy (OR 2.29, CI 1.4–3.7). The results for other
AED groups may be influenced by a lower statistical power,
as there were numerical increased risks for several variables
(Appendix S1). There is a possibility that polytherapy may
have an effect, but rates of polytherapy were similar in all
AED groups studied.
Strengths of the present study include a large study popu-
lation and a prospective design. The participation rate of
41% at first assessment is as expected for population-based
studies.40 Because filling out the questionnaires requires
some effort, it is possible that the MoBa participants were
more resourceful than nonparticipants. However, this is not
expected to influence or bias effect measures.9 A strength of
the present study is the inclusion also of women with
resolved/inactive epilepsy who were not using AEDs during
pregnancy. A retrospective study of the MoBa cohort
showed that the frequency of seizures during pregnancy in
women not taking AEDs was 10.7% the last 2 years and
16.8% the last 5 years before pregnancy.11 A self-reported
diagnosis of epilepsy might be less accurate than a diagnosis
reported by medical professionals. However, the epilepsy
diagnosis and medication were validated by linkage to the
MBRN, hospital records (diagnosis not confirmed for 5%),
blood samples (detection rate 95%), and with a retrospective
questionnaire (PPV 98.8%, specificity 99.9%).10,11 There
was no significant difference in the prevalence estimates of
epilepsy in the MoBa cohort and the total population.9 Com-
plications during pregnancy, delivery, and birth outcome
were reported by midwives and physicians. Given that the
MoBa study contains >100,000 participants, the statistical
power in our study was high. Nevertheless, some AED sub-
groups were underpowered, and we were not able to do
monotherapy analyses. However, the proportion of poly-
therapy users was similar in all AED groups.
Conclusion
Our results show that the combination of overweight and
epilepsy exposes mother and child to a significantly
increased risk of complications during pregnancy and in the
perinatal period. Overweight is a preventable risk factor.
Referral to a nutritionist should be considered for young
women with epilepsy when an AED is initiated and when
pregnancy is planned. Exercise should be encouraged to
reduce weight. Overweight and obese women with epilepsy
should be regarded as a high-risk group during pregnancy
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preeclampsia, hypertension, intrauterine growth restriction,
as well as perinatal depression and anxiety should be moni-
tored. Heredity, physical activity, lifestyle, antiepileptic
medication, and diet are all probable mediators for over-
weight and obesity in epilepsy.
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Young people with epilepsy have an increased risk of eating
disorder and poor quality diet
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Objective: To investigate whether adolescents with epilepsy are at increased risk of
having self-reported eating disorder symptoms and poor quality diet compared to
young people from the general population.
Methods: We used data from the Health Profile for Children and Youth in Akershus
Study, a cross-sectional population-based study based on a voluntary self-reported
questionnaire. There were 19,995 participants (response rate 85%) aged 13–19 years;
247 (1.2%) reported a lifetime diagnosis of epilepsy. Odds ratios (OR) and 95% confi-
dence intervals (CI) for eating disorders, unhealthy diet, dieting, satisfaction with
looks, and participation in sports were estimated by using a logistic regression model.
All estimates were adjusted for single parents and poor family economy.
Results: Children and adolescents with epilepsy had more eating disorders than their
peers (OR 1.8, CI 1.0–3.0, p = 0.03). They were less satisfiedwith their own appearance
(OR 0.7, CI 0.5–0.9, p = 0.02), and they eat more unhealthily (OR 1.7, CI 1.3–2.2,
p = 0.001). Males with epilepsy were more likely to have been dieting (OR 3.1, CI 1.2–
7.9, p = 0.02) and less satisfied with their own appearance (OR 0.4, CI 0.3–0.7,
p < 0.001). Females with epilepsy were more likely to eat unhealthily (OR 1.7, CI 1.1–
2.5, p = 0.01).
Significance: Adolescents with epilepsy are at increased risk of having eating disorder
symptoms. They eat less healthily and are less satisfied with their looks. Health work-
ers should be aware of this and bring diet and lifestyle into the dialoguewith young peo-
ple with epilepsy.
KEYWORDS: Epileptic, Psychiatric, Adolescents, Overweight, Children.
Epilepsy is a common neurological disorder with a preva-
lence of 0.6–1.2%.1–3 Epilepsy in adolescents is associated
with comorbid disorders such as depression, anxiety, atten-
tion-deficit/hyperactivity disorder (ADHD), and low self-
esteem.4–7 Boys with epilepsy are prone to risk-taking
behavior.8 The relation between epilepsy and eating disor-
ders has been scarcely studied, and not at all in adolescents.
A population-based study from England found an increase
in risk of eating disorders among people with epilepsy in
general.3 Pregnant women with epilepsy in Norway also
more frequently reported an eating disorder than other
women, especially binge eating disorder.9,10 The prevalence
of eating disorders among adolescents continues to
increase11 and is a predictor of negative outcome in terms of
mental health disorders, substance abuse, deliberate self-
harm, and overweight or underweight.12,13 Thus, there is a
demand for further knowledge within this field. Our aim
was to investigate whether adolescents with epilepsy more
often than their peers had eating disorder symptoms and eat-
ing-associated problems such as frequent dieting and
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negative feelings toward their own appearance. We also
wanted to study quality of diet in adolescents with epilepsy.
Methods
We used data from the Health Profile for Children and
Youth in Akershus Study.14 This cross-sectional popula-
tion-based study was based on a voluntary self-reported
questionnaire. The relevant questions for this investigation
are listed in the Appendix. The study was conducted by the
Norwegian Health Services Research Centre in 2002. Ran-
dom school classes from all municipalities in Akershus
County were selected, and all pupils aged 13–19 years in
the selected classes were invited to participate. Their par-
ents were informed and gave consent. A total of 19,995
adolescents answered, yielding an 85% response rate; 0.4%
of pupils in Norway attended special schools in 2002 and
were excluded from this study.15 Special schools are for
children and adolescents with disabilities such as mental
retardation. The questionnaire comprised 110 questions
grouped under the main topics: sociodemographic condi-
tions, social network and school, smoking, alcohol, drug
abuse, nutrition and attitude concerning body, physical
health, psychosocial health, mental health, use of health
services.16 The questionnaires were completed during a
classroom session and were all anonymous.
The epilepsy diagnosis was self-reported. The participants
answered the simple question of whether they had or had had
epilepsy. This question could be answered by “yes,” “no,” or
“don’t know.” The answer “yes” counted as having epilepsy,
and “no” and “don’t know” counted as not having epilepsy.
Two hundred forty-seven individuals (1.2%) reported a diag-
nosis of epilepsy. In an exploratory analysis those who
answered “don’t know” were excluded. All other participants
constructed the reference group. Questions concerning
asthma were asked in the same way as for epilepsy. All indi-
viduals reporting this diagnosis formed a control group of
chronic disease (n = 3,320). This group was also a part of
the total reference group (n = 19,748).
Outcome variables
For the purposes of this investigation, reporting having
sought help from health personnel for an eating disorder
was used as a proxy for a diagnosis of an eating disorder.
Participants reported whether they had visited a school
nurse or other health personnel with an eating disorder as
the main issue. Participants’ diet was investigated. An
unhealthy diet was defined prestudy by nutritionists as eat-
ing or drinking candy, potato chips, french fries, or sugar-
containing soda daily. The participants reported whether
they were or previously had been on a diet to reduce weight.
They also noted whether they were satisfied with their own
body appearance (yes/no) and whether they wanted to
improve their looks (yes/no). Finally, the level of physical
exercise was recorded. Participants reported how often they
were physically active, and the alternatives were (1) never,
(2) less than once a month, (3) once a month, (4) once a
week, (5) 2–3 times a week, (6) 4–6 times a week, and (7)
every day. A dichotomous variable was constructed where
the cut-off was set at being physically active two or more
times a week. Mean age of menarche was calculated for
female participants.
Covariates
Perceived low family income, living with a single parent,
and depressive symptoms were used as covariates. Depres-
sive symptoms were assessed using SDQ-S (Strength and
Difficulty Questionnaire), a tool frequently used to screen for
psychiatric symptoms with good psychometric properties.16,17
These data has been reported for this population previously.8
The appropriate questions are listed in the Appendix.
Statistics
For statistical analysis we used SPSS version 22. Chi-
square tests (Fisher exact test for an expected cell count <5)
and t test were used to investigate group differences, and
odds ratios with 95% confidence intervals were obtained
using logistic regression. The logistic regression models
were adjusted for reported low family income and living
with a single parent. Both logistic univariate and multivari-
able analyses were performed to investigate associations
between variables. Eating disorder was set as the dependent
factor and dieting, unhealthy diet, satisfaction with own
body appearance, desire to change looks, depressive symp-
toms, and age, sex, overweight, family economy, single par-
ent, and smoking as independent factors within the epilepsy
group. The independent factors were first tested separately
in univariate analyses. Criterion for variables to enter the
multivariate analysis was set at p < 0.1. Satisfaction with
own body appearance and desire to change looks were not
included in the same multivariate analysis owing to
collinearity with dieting.
The study was approved by the regional ethics committee
(REK, ref. 40-02022).
Results
Background information is provided in Table 1. Mean
age and mean height were similar in the epilepsy and refer-
ence populations as well as for the group with other chronic
Key Points
• Adolescents with epilepsy are at an elevated risk of
suffering from eating disorder symptoms
• They eat less healthily and are less satisfied with their
looks
• Referral to a nutritionist should be considered in
young people with epilepsy at the time of diagnosis
Epilepsia Open, 3(1):40–45, 2018
doi: 10.1002/epi4.12089
41
Epilepsy, eating disorders, and diet
diseases. The epilepsy group and the group with other
chronic disease were significantly heavier than the refer-
ence group and more often reported nicotine smoking.
People with epilepsy between 13 and19 years more often
reported having an eating disorder (OR 1.79, CI 1.0–3.0,
p = 0.03) and an unhealthy diet (OR 1.67, 1.3–2.2,
p = 0.001) than the reference group. Young people with
epilepsy had a significant higher daily consumption of
candy, sugar-containing soda, potato chips, and pommes
frites than adolescents without epilepsy (Fig. 1). They were
also significantly less satisfied with their own body appear-
ance (OR 0.69, CI 0.5–0.9, p = 0.02) (Table 2; Fig. 2).
Results did not change when people who did not know
whether they had epilepsy or not were excluded from the
analysis.
Females with epilepsy were more prone to an unhealthy
diet (OR 2.16, CI 1.5–3.2, p = 0.001) compared to females
in the reference group (Fig. 3). Males with epilepsy were
more likely to be dieting (OR 3.12, 1.2–7.9, p < 0.02) than
their peers and reported being less satisfied with their body
appearance (OR 0.44, 0.3–0.7, p < 0.001) (Fig. 4). These
differences were not as prominent in females with epilepsy
(Fig. 3). A group of adolescents with the chronic disease
asthma scored in between the epilepsy group and the refer-
ence group for all variables (Table 2).
There was no difference in age of menarche in the epi-
lepsy group (mean age 12.6, SD 1.4) and the reference
group (mean age 12.6, SD 1.2).
In the univariate logistic regression analysis within the
epilepsy group there was a significant inverse association
between eating disorder and satisfaction with looks (OR
0.2, CI 0.06–0.58, p = 0.004), between an eating disorder
and a desire to change looks (OR 5.1, CI 1.8–15.1,
p = 0.003), and between seeking help for eating disorders
and dieting (OR 89.3, CI 4.5–542.0, p < 0.001), although
CI for the latter analysis was wide. There was no significant
association between eating disorder and depressive symp-
toms, with family economy, living with a single parent, or
with being overweight (OR 1.44, CI 0.5–4.5, p = 0.53).
However, there was an association between satisfaction
with looks and family economy (OR 3.58, CI 1.5–8.7,
p = 0.005). There was an inverse association in the epilepsy
group between satisfaction with looks and dieting (OR 0.05,
CI 0.01–0.2, p < 0.001). Only dieting remained signifi-
cantly associated with having an eating disorder in the mul-
tivariate model (OR 47.9, CI 4.5–511.9, p = 0.0.1).
Discussion
Key findings
Our main finding is an increased rate of eating disorder
symptoms in an unselected and population-based cohort of
adolescents with epilepsy compared with a reference group.
This is an important finding in a group that is known to be at
risk of several psychiatric disorders.5,9,16,18 Better knowl-
edge should increase awareness and lead to a better holistic
treatment of epilepsy. Apart from their immediate impact,
eating disorders can result in physical problems later in life,
such as impaired bone density, reduced skeletal function,19
and impaired reproductive health in women.20 Perhaps more
importantly, however, eating disorders also represent a pre-
dictor of mental health disorders, substance abuse, and
deliberate self-harm.12,13 The presence of an eating disorder

















Age (SD) 16.1 (1.4) 16.2 (1.5) 16.1 (1.4) 16.2 (1.5) 16.1 (1.4) 16.2 (1.5) 16.2 (1.5)
Height in cm (SD) 174.7 (9.4) 173.8 (9.0) 180,5 (7.5) 179.8 (7.1) 167.5 (6.5) 167.4 (6.0) 173.3 (9.2)
Weight in kg (SD) 67.5 (11.8)* 65.4 (11.7) 72,8 (11.4) 71.3 (11.1) 60.9 (9.0) 59.1 (8.8) 66.2 (12.1)**
Smoking (%) 78 (32.9%)** 4,180 (24.2%) 45 (34.4%)*** 1,877 (21.4%) 33 (31.4%) 2,278 (27.0%) 913 (28.0%)***
Overweight BMI >25 n (%) 13 (13.0%) 1,047 (12.6%) 8 (13.8%) 677 (15.7%) 5 (11.9%) 364 (9.2%) 246 (15.9%)***
Obesity BMI >30 n (%) 2 (2.0%) 172 (2.1%) 1 (1.7%) 102 (2.4%) 1 (2.4%) 69 (1.7%) 45 (2.9%)*
BMI, body mass index; SD, standard deviation.
*p < 0.05, **p < 0.01, ***p < 0.001 compared to the reference group.
Figure 1.
Eating-related factors in the epilepsy group (n = 247) vs. the refer-
ence group (n = 19748).
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before pregnancy has been associated with a greater likeli-
hood of pregnancy complications in patients with epilepsy.9
This is also seen among the general population, where
maternal eating disorders have been associated with
impaired fetal growth and impaired growth in the children
during their first year.21 Furthermore, children of mothers
with eating disorders have been shown to be at increased
risk of psychiatric disease in childhood.22 This highlights
the importance of early detection and intervention regarding
eating disorders, both in the general population, but espe-
cially among patients with epilepsy who may also have
additional problems.
The etiology of eating disorders is largely unknown. Both
genetic predisposition and environmental and sociocultural
influences are thought to be relevant etiologic factors for
eating disorders,23 but none of these should be specific for
epilepsy. However, some antiepileptic drugs (AEDs) con-
tribute to a weight increase,24 and eating disorders may arise
as a response to these changes. Another contributing factor
may be that failure to control seizures may prompt a need in
patients with epilepsy to gain control over their body in a



















Eating disorder n (%) 8 (5.4%)** 210 (2.0%) 3 (4.3%)* 50 (1.1%) 5 (6.7%)* 159 (2.8%) 54 (2.7%)*
Dieting n (%) 13 (5.3%) 655 (3.7%) 5 (3.6%)** 94 (1.1%) 8 (7.4%) 559 (6.5%) 148 (4.5%)*
Unhealthy diet n (%) 119 (51.7%)*** 6,718 (39.0%) 65 (52.8%) 3,919 (45.0%) 54 (54.9%)*** 2,762 (32.7%) 1,481 (48.0%)**
Wants to improve
looks n (%)
60 (24.3%) 3,490 (19.8%) 21 (15.3%)* 903 (10.1%) 39 (36.1%) 2,577 (30.1%) 657 (19.8%)
Satisfied with looks n (%) 174 (77.0%)* 14,258 (83.2%) 104 (83.9%)*** 8,004 (92.6%) 70 (68.6%) 6,187 (73.5%) 2,589 (80.6%)***
Participates in sports n (%) 158 (66.7%) 11,636 (66.9%) 82 (63.6%) 6,292 (71.4%) 75 (70.1%) 5,285 (62.1%) 2,220 (67.8%)
*p < 0.05, **p < 0.01, ***p < 0.001 compared to the reference group.
Figure 2.
Eating-related factors in males with epilepsy (n = 137) vs. males in
the reference group (n = 10180).
Epilepsia Open ILAE
Figure 3.
Eating-related factors in females with epilepsy (n = 108) vs.
females in the reference group (n = 9703).
Epilepsia Open ILAE
Figure 4.
Frequency (percent) of young people with a daily consumption of
various food categories in the epilepsy (n = 247) vs. the reference
group (n = 19748). ***p < 0.001 compared to the reference
group.
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different way. By focusing attention on weight, shape, and
eating, epilepsy patients may feel that they are in a domain
where control is possible.25 Furthermore, people with epi-
lepsy have a higher burden of psychiatric comorbidity, such
as anxiety and depression,26 and eating disorders could be
associated with these conditions. Anxiety and depression
are frequent comorbid conditions in people with eating dis-
orders.13 However, in our material there was no association
between an eating disorder and depressive symptoms within
the epilepsy group.
In our study, adolescents with epilepsy appeared to have
a diet of poorer quality than their peers without epilepsy. An
unhealthy diet is a growing concern and a major cause of
morbidity and disability worldwide,27 partly because it
leads to overweight and obesity. These conditions are
mainly concerns of developed countries and could also be
seen as a socioeconomic problem.28 However, despite the
less healthy diet in the young people with epilepsy, we did
not find an increased rate of overweight, although they were
heavier. Increased frequency of overweight in patients with
epilepsy has been reported in other cohorts.29
The chronic disease asthma scored in between the epi-
lepsy group and the reference group in terms of risk of eat-
ing disorder, dieting, unhealthy diet, and dissatisfaction
with own appearance. This emphasizes that young people
with epilepsy are especially vulnerable in terms of develop-
ing bad eating habits and eating disorders.
A risk of eating disorders and poor diet quality should be
evaluated in young people with epilepsy, and referral to a
nutritionist at the time of diagnosis as well as when starting
on AEDs should be considered. Exercise and a healthy life-
style should be encouraged in all adolescents but particu-
larly among those with epilepsy. In some cases exercise will
help control seizure frequency.30
Dissatisfaction with own body appearance was more fre-
quent in adolescents with epilepsy than in the reference
group. This may reflect the stigma that many epilepsy
patients feel influences their lives,31 which affects their
quality of life and leads to anxiety and depression. An
increased rate of hyperactivity/inattention problems, anxi-
ety, and depression has previously been reported also in our
epilepsy cohort.5 Dissatisfaction with own appearance was
associated with dieting and a wish to improve looks. There
was also an association between poor family economy and a
dissatisfaction with own body appearance.
Strengths and limitations
A large sample size and very high response rate (85%)
are the main strengths of this study. A major strength is
also the population-based nature of the study. Because a
large proportion of the invited youths participated, we
avoided the overestimation of adverse outcomes that
often occurs in clinical materials. Randomization of
selected school classes was performed, and, because of
the organization of the Norwegian school system with
almost all children (>96% in 2015) attending ordinary
state-funded schools, an accurate representation of the
population was obtained. Our reference group consisted
of youths who were representative of the general popula-
tion and not only healthy individuals; hence we avoided
inflation of the rates of adverse outcomes in the epilepsy
group. We were also able to compare the epilepsy group
with a relevant control group with a nonneurological
chronic disease and to assess the relationship between
epilepsy, eating disorders, diet, and socioeconomic status.
The main limitation of this study is the lack of clinical
information, such as type of eating disorder, type of epi-
lepsy, seizure frequency, and treatment. In addition, we
were not able to classify the types of eating disorder.
Adolescents with severe disabilities, including severe
mental retardation, were excluded from this study if they
were not attending general public schools (0.4% of pupils
in Norway in 2002).15 This means that we have possibly
excluded people with the most disabling epilepsy but
also we have excluded those with similar disabilities
who are not epileptic. It might be assumed that our
findings would be even more pronounced if only
people with active epilepsy and using AEDs had been
included.
Significance
Both female and male adolescents with epilepsy are at an
elevated risk of suffering from eating disorder symptoms.
They eat less healthily than their peers without epilepsy and
are less satisfied with their own appearance. Health workers
should be aware of these associations between epilepsy, eat-
ing disorders, and diet and introduce diet and lifestyle into
their dialogues with young people with epilepsy. Referral to
a nutritionist should be considered in young people with epi-
lepsy at the time of diagnosis as well as when initiating
antiepileptic medication.
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Appendix Items from
questionnaire used in the paper:
1 Are you male or female?
2 In what year were you born?
3 Do you live with your mother, father, or both?
4 Howmuch do you weigh?
5 How tall are you?
6 Do you have or have you had asthma, diabetes, or epi-
lepsy? (yes/no)
7 Do you smoke? (yes/no)
8 How often do you smoke? (1. Not at all. 2. Less than
once a week. 3. Every week. 4. Every day.)
9 How often do you participate in sports? (1. Not at all. 2.
Less than once a month. 3. Once a month. 4. Once a
week. 5. 2–3 times a week. 6. Every day.)
10 How often do you eat/drink fruit, vegetables, whole-
wheat bread, dairy products, potatoes, candy, juice,
sugar-containing soda, potato chips, hamburger, and
sausages? (1. seldom/never. 2. Less than once a week. 3.
Once a week. 4. Several times a week. 5. Every day. 6.
Several times a day.)
11 Have you ever tried dieting to lose weight? (yes/no)
12 Are you satisfied with your appearance? (yes/no)
13 Do you want to change your appearance? (yes/no)
14 How old were you when you first had your period?
15 Have you ever sought help of health personnel because
of an eating disorder? (yes/no)
From Fig. 1: Analyses where the epilepsy group is com-
pared to a reference group that denied having epilepsy.
Those who answered “don’t know” are excluded.
OR (CI) p-value
Eating disorder 1.82 (1.1–3.1) 0.02
Dieting 1.48 (0.8–2.6) 0.2
Unhealthy diet 1.47 (1.1–1.9) 0.005
Wants to improve looks 1.08 (0.8–1.4) 0.5
Satisfied with looks 0.67 (0.5–0.9) 0.01
Participates in sports 1.2 (0.8–1.7) 0.2
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